1 A causal role for estradiol in human reinforcement learning

2

3 Authors

Sebastijan Veselic^{1,2,3*}, Gerhard Jocham⁴, Christian Gausterer⁵, Bernhard Wagner⁶, Miriam
Ernhoefer-Reßler⁶, Rupert Lanzenberger⁷, Claus Lamm^{1,8}, Christoph Eisenegger¹ & Annabel
Losecaat Vermeer^{1*}

7

8 Affiliations

- ⁹ ¹Neuropsychopharmacology and Biopsychology Unit, Department of Cognition, Emotion,
- 10 and Methods in Psychology, Faculty of Psychology, University of Vienna, Austria
- ² Department of Clinical and Movement Neurosciences, University College London, London,

12 UK

- ¹³ ³Wellcome Centre for Human Neuroimaging, University College London, London, UK
- ⁴ Biological Psychology of Decision Making, Institute of Experimental Psychology, Heinrich
- 15 Heine University Düsseldorf, Germany
- ⁵ FDZ-Forensisches DNA Zentrallabor GmbH, Medical University of Vienna, Austria
- ⁶ Laboratory for Chromatographic & Spectrometric Analysis, FH JOANNEUM, Graz, Austria
- ⁷ Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna,
- 19 Austria,
- 20 ⁸ Vienna Cognitive Science Hub, University of Vienna, Austria
- 21
- 22
- 23 (*) corresponding authors: Sebastijan Veselic (sebastijan.veselic.18@ucl.ac.uk) and
- 24 Annabel Losecaat Vermeer (annabel.losecaat.vermeer@univie.ac.at)

25 Abstract

26 The sex hormone estrogen is hypothesized to play a key role in human cognition via its 27 interactions with the dopaminergic system. Work in rodents has shown that estrogen's most 28 potent form, estradiol, impacts striatal dopamine functioning predominately via increased D1receptor signalling, while human work has suggested that high estradiol levels are associated 29 with altered reward sensitivity. Here, we addressed two fundamental questions: 1) whether 30 estradiol causally alters reward sensitivity in men, and 2) whether this effect of estradiol is 31 32 moderated by individual variation in polymorphisms of dopaminergic genes. To test this, we performed a double-blind placebo-controlled administration study in which hundred men 33 received either a single dose of estradiol (2 mg) or placebo. We found that estradiol 34 35 administration increased reward sensitivity, which was moderated by baseline dopamine. This 36 was observed in choice behaviour and increased learning rates. These results confirm a causal role of estradiol in reinforcement learning in men that is moderated by the striatal 37 dopaminergic pathway. 38

39

Keywords: Estradiol, reward processing, reinforcement learning, DAT1, COMT, Estrogen
receptor

42 Introduction

Learning which action to select based on whether the outcome of that action is rewarded or not is a fundamental capacity required for adaptive behaviour. One neuromodulator that has long been linked to this capacity, known as reinforcement learning (RL), is dopamine ¹. More recently, an additional biological substrate that has been suggested to influence RL via dopaminergic mechanisms is estrogen ².

Estrogens are a class of steroid hormones important for healthy development, with 48 estradiol being the most prevalent and potent form ^{3,4}. Estradiol has gained traction as a 49 compound that may impact human reward processing by amplifying dopamine signalling via 50 the D1 receptor ². The evidence for this hypothesis comes from two lines of work. From human 51 work, we know that fluctuations in circulating estradiol levels are correlated with differences in 52 midbrain BOLD responses, a key area where dopamine is released ^{5–7}. Furthermore, a recent 53 administration study in women showed that increased salivary estradiol levels led to larger 54 reward prediction errors in the nucleus accumbens 8. From rodent work, we know that 55 manipulating estradiol levels affects the striatal dopamine system in various ways that are best 56 57 characterised as a net increase in overall dopamine signalling predominantly via the D1 receptor 9-14. 58

If increased estradiol levels in humans influence reward processing by increasing 59 reward sensitivity through amplified dopamine signalling via the D1 receptor, then it should be 60 possible to relate its effects to that of dopamine in RL^{1,15–17}. Within this field, dopamine agonists 61 and antagonists are often administered to better understand the mechanistic role of dopamine 62 in RL¹⁸⁻²⁴. Complementing it with pharmacogenetics, where the effect of genetic variation on 63 the administered drug is considered, has refined our understanding of their relationship ^{19,22,25-} 64 65 ²⁷. That is, causally manipulating dopamine levels in humans affects performance in RL tasks²⁷ 66 with these effects depending on individual differences in baseline dopamine levels ¹⁸.

Two key polymorphisms that lead to variation in baseline dopamine levels by impacting dopamine synthesis capacity and transmission are the dopamine transporter (DAT1) and

69 catechol-O-methyltransferase (COMT) gene ^{19,24,25}. Variation in the VNTR polymorphism of 70 DAT1 and the val¹⁵⁸met polymorphism of COMT correlates with performance on working 71 memory and RL in humans ^{19,24,25,28,29}. Therefore, if estradiol influences reward processing 72 through dopaminergic mechanisms, then variation in the DAT1 and COMT genotype should 73 moderate the effect of estradiol. Furthermore, we would predict it should be moderated by 74 traits related to human reward sensitivity such as the ones measured by the BIS/BAS 75 questionnaire ^{30–33}.

76 Despite abundant evidence from rodent research showing a clear relationship between 77 estradiol and dopamine, evidence in humans have been less conclusive. Namely, it has been shown that high endogenous estradiol levels were associated with increased ^{5,7} as well as 78 decreased ³⁴ performance on a variety of cognitive tasks that may have recruited different 79 neural mechanisms. Thus, it remains unclear whether administering estradiol influences 80 81 reward processing as would be expected by amplified D1-receptor signalling. Furthermore, although previous work on humans provided important insights, it had certain shortcomings 82 such as small sample sizes, correlational study designs, and a lack of accounting for baseline 83 differences in dopamine; for exceptions see ^{8,34,35} ^{25,36}. All studies thus far have also focussed 84 85 on female samples who have, on average, higher endogenous levels of estradiol compared to men ³⁷. These aspects are important for being able to establish a more precise role of 86 estradiol in human reward processing which, therefore, remains an open question (for review 87 see²). 88

The aim of the present pharmacogenetic study was to address these gaps and 89 investigate whether estradiol administration increases reward sensitivity in men and whether 90 91 this effect is moderated by baseline differences in dopamine. To test this, we used a 92 probabilistic RL task (Fig. 1A) where subjects had to choose between two options on each trial in order to maximize their earnings. Moreover, we aimed at providing a more conclusive and 93 precise account of a dopamine-dependent basis of action through excluding several other 94 95 candidate explanations (i.e. gene polymorphisms) that could have given rise to the obtained 96 results and have so far been unaddressed in the literature (see Supplementary Materials).

97 We hypothesized that estradiol administration would influence reward processing by 98 increasing reward sensitivity observed through subjects' choice behaviour ⁸. We further 99 predicted this would be revealed through computational modelling. Finally, we predicted that 100 the behavioural and computational effects would be moderated by the DAT1 polymorphism, 101 as observed in previous dopamine administration work ^{19,26}.

102

103 Methods and materials

104 Subjects

We tested one hundred healthy young men between 19 and 34 years ($M_{age} = 24.86$, SD =3.53) with a body mass index (BMI) between 19.3 and 31.5 (M = 24.45, SD = 2.86). Our screening procedure was based on previous work where pharmacokinetic data for a single 2 mg estradiol dose in topical form was obtained ³⁸. Our sample size was in line with previous recommendations for the field ². The study procedure was performed in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of the University of Vienna (1918/2015).

112 Measurement Instruments

113 **Questionnaires**

We assessed self-reported mood (German Multidimensial Mood State Questionnaire; MDBF³⁹), individuals' impulsiveness (Barratt Impulsiveness Scale; BIS-11⁴⁰), and behavioural activation and inhibition (BIS/BAS⁴¹). Both BIS/BAS and BIS-11 scores have been previously found to correlate with reward learning ^{42–45} with the BIS/BAS specifically being related to reward sensitivity ^{30,31}. In addition, we probed subjects' beliefs about estradiol (e.g. whether they believed they received estradiol or a placebo, how certain they were about their belief, and whether they had noticed any subjective changes).

122 Hormone concentrations

We collected hormone samples via passive drool and stored them at -30 degrees Celsius. Saliva samples were analyzed for estrone and estradiol using gas chromatography tandem mass spectrometry (GC-MS/MS) and hydrocortisone including testosterone with liquid chromatography tandem mass spectrometry (LCMS/MS).

127 Genotyping

We collected DNA using sterile cotton buccal swabs (Sarstedt AG, Germany) and extracted it by applying the QIAamp DNA Mini kit (Qiagen, Germany). Repeat length polymorphisms (AR(CAG), AR(GGN), DAT1(VNTR), ER α (TA) and ER β (CA)) were investigated by PCR with fluorescent-dye-labeled primers and capillary electrophoresis. The single base primer extension (SBE) method also known as minisequencing was applied for the typing of single nucleotide polymorphism (SNP) variants (Val158Met) in the COMT gene.

134 Experimental Tasks

Reinforcement Learning: We used a well-established probabilistic reinforcement learning 135 task with two options ¹⁷. The task consisted of 500 trials, with a 10 second pause after the first 136 250 trials. There was no choice time-out. The two options had independently varying reward 137 138 probabilities generated by Gaussian random walks (Fig. 1). Importantly, both options could be correct (i.e. rewarding - yellow frame) or incorrect (i.e. non-rewarding - reward frame) on any 139 trial. Subjects received feedback for the chosen (thick frame) and unchosen (thin frame) 140 141 option. Each correct choice was rewarded with 5 eurocents and added to their cumulative balance. Subjects also saw a bar fill up as they chose the correct option. Once the bar filled 142 up, a 1 € coin was presented next to the bar indicating they had added 1 € to their cumulative 143 balance. 144

Working memory capacity: We used an adapted version of the standard N-BACK task ²⁵
with four conditions in total (0-BACK, 1-BACK, 2- BACK, 3-BACK). Each condition block had
20 trials which included 20% target, 65% nontarget, and 15% lure trials. Subjects were


presented with a sequence of letters one-by-one. For each letter, they had to decide if the current letter was the same as the one presented *N* trials ago by pressing "R", in case it was not the same they had to press "O".

151 Procedure

Subjects screened for BMI, a history of psychiatric disorders, concurrent involvement in other psychopharmacological studies, and chronic physical injuries, arrived to the lab on two separate days. On the first session, at 4.00 pm, we collected subjects' responses on a battery of questionnaires, their DNA with a buccal swab for genotyping, and measured their BMI and body fat using a body composition monitor (Omron BF51).

157 On the second session (Fig. 1, timeline) after obtaining consent, subjects filled out the MDBF-A, BIS-11, and BIS/BAS. Twenty minutes after arrival, we obtained the first saliva 158 sample (T1) to assess baseline hormone concentrations, followed by the N-BACK task. They 159 160 were randomly assigned estradiol or placebo in a double-blind manner and self-administered a topical transparent gel containing either 2 mg of estradiol or a placebo. We waited two hours 161 to allow estradiol levels to peak based on a previously established procedure ³⁸. Fifteen 162 minutes prior to the behavioural testing, subjects filled out MDBF-B, BIS-11, and provided a 163 164 second saliva sample (T2).

165 The first behavioural task was the probabilistic reinforcement learning task, followed 166 by three other tasks that were not the focus of this publication. After the behavioural testing, 167 we probed subjects' beliefs about the treatment and the tasks. At the end of the study, each 168 subject was paid in accordance to their performance.



170

Fig. 1 A) Outline of a trial of the RL task. Each trial started by the presentation of two options (henceforth 171 option A and option B). Subjects were required to choose one of these options. After they made a 172 173 choice, subjects were presented with feedback, with the chosen option indicated by a thicker frame and 174 the not chosen option by a thinner frame. A vellow frame indicated the rewarded option, whereas a red 175 frame indicated the unrewarded option. Importantly, both options A and B could yield a reward or no 176 reward on the same trial. B) The probability of reward upon choice for each option (green and gray lines), which were determined by two independent random Gaussian walks, with the probability shown 177 in percent on the right y-axis in orange. The black line shows the relative probability of reward for one 178 179 option over the other, which corresponds to the difference in reward probability for option A and option B. On trials where the black line is reaching the top half of the y-axis, option A was more rewarding, and 180 vice versa. C) The timeline of the test session. Values in brackets denote minutes from the onset of the 181 182 test session. We first collected consent and questionnaire data, which was followed by a baseline saliva 183 sample (T1) and the N-BACK task. After administration of estradiol or placebo, subjects were required 184 to rest for two hours before we collected the second saliva sample (T2) and assessed subjects' mood and impulsivity via questionnaires. The RL task began 120 minutes post-administration. This was 185 followed by three other cognitive tasks that are not the focus of the current paper. At the end of the test 186 187 session, we probed subjects' beliefs about the drug, the experiment, and debriefed them.

- 188
- 189
- 190
- 191
- 192
-
- 193
- 194

195 Statistical analysis

196 Behavioural analysis

197 To determine the effect of estradiol on choice behaviour, we examined the cumulative 198 difference in the options subjects chose and the percentage of trials on which there was a 199 significant difference in the chosen option. As a measure of family-wise error control, we used 200 permutation testing and Fisher-z-transformations.

We also computed choice accuracy because we predicted that if estradiol would influence reward processing by increasing reward sensitivity, this would result in increased accuracy and be moderated by differences in striatal dopamine functioning (i.e. through the DAT1 genotype) ²⁶. Due to the same reasoning we computed how many trials subjects would pick the same option if they were rewarded for that option on trial *t* (staying). Accuracy and staying were statistically evaluated with general linear models.

207 In addition to the above metrics, we computed subjects' choice autocorrelation. With 208 this, we tested our hypothesis that increased reward prediction errors would, by definition, upregulate saliency of recent events⁸. Behaviourally, this would mean subjects' recent 209 choices should influence what they will choose next more. We computed the relative 210 contribution of choices made from n - 1 to n - 7 trials back (lags) on the current choice. We 211 then compared the relative contribution of all previous choices (pure choice autocorrelation) 212 and specifically choices when they were rewarded (choice autocorrelation as a function of 213 reward). We then performed independent samples t-tests on individual lags that were z-scored 214 within subject to assess statistical significance. 215

216 Computational modelling

To account for behaviour within a computational framework and relate our findings to the field exploring dopamine and its role in RL, we used computational modelling. We fit a series of Qlearning models with softmax choice rules. The winning model included a learning rate for positive and negative prediction errors, a temperature parameter, and an irreducible noise parameter (see Supplementary materials for model selection and parameter recovery). Our main hypothesis was that if estradiol would increase reward sensitivity, that should be captured by the learning rate, reflecting how strongly new information will be weighed and incorporated into the subjects' subjective values.

225

226 **Results**

227 Our sample was matched for age, height, visceral, and abdominal fat, BMI, working memory, self-reported impulsivity, behavioural inhibition and approach, and mood. As a manipulation 228 check of our administration protocol, estradiol concentrations were significantly elevated in 229 230 subjects who had received estradiol compared to placebo after (W = 1545, 95% CI [0.03, 1.87], p < .05), but not before administration (baseline: W = 1498, 95% CI [-0.05, 1.03], p =231 .09) and subjects' beliefs about whether they had received estradiol or placebo did not 232 correlate with the actual received drug (r = 0.02, p = .82; for further details see Supplementary 233 234 Materials).


235 Estradiol administration increases reward sensitivity

Our first hypothesis was that estradiol administration would increase reward sensitivity. Because reward size was kept constant, the only difference across trials was whether a choice was rewarded or not. Therefore, we predicted that increased reward sensitivity would be reflected in a systematic difference in the options subjects would choose across trials compared to placebo. To test this, we computed the average probability per group to select option A/B (i.e. expected chosen option) on each trial (Fig. 2A), subtracted these traces from each other, and plotted the cumulative choice difference across trials (Fig. 2B).

The cumulative choice difference in the expected chosen option between both groups surpassed what would be expected by chance. This was tested by comparing the above results to the 99.9th percentile of a null distribution (see Methods and materials) indicating what would be expected by chance ($M_{\text{last trial}} = 53.48$ %, $z_{\text{last trial}} = 8.44$, p < .001, threshold for 99.9th percentile of the null: 46.20 %, Fig. 2B). The observed cumulative choice difference remained significant when collapsed across time ($M = 25.72 \pm 0.69\%$, z = 5.80, p < .001, threshold for 99.9th percentile of the null: M = 21.02 %, Fig. 2C). When we traced trials that contributed most to the cumulative difference, we observed a statistically significant difference in what both groups chose on 7.6 % of trials (black dots in Fig. 2A). In other words, estradiol administration caused subjects to choose a different option on 7.6 % of trials as compared to placebo (z = 5.37, p < .001, threshold for 99.9th percentile of null distribution: 6.4 %).

However, estradiol administration did not only increase reward sensitivity in choice behaviour as described above. When subjects rated how strongly they observed the changing of reward probabilities of both options throughout the task on a scale from 1 to 100 during debriefing, those receiving estradiol explicitly reported that they observed reward probabilities across trials to change more strongly ($t_{(78.495)} = 2.15$, 95% *Cl* = [0.855, 22.61], *p* = 0.035, *d* = 0.48, *BF*₁₀ = 3.28).





261 Fig. 2 A) Relative choice probability for choosing option A (top of y-axis) vs. choosing option B (bottom of y-axis) for the estradiol (orange) and placebo (gray) group. Solid thick lines represent trial mean, 262 263 shaded areas around the thick lines denote standard errors of the mean. The blue dotted line denotes 264 the relative reward probability which was computed from the probability of option A (top of y-axis) minus 265 probability of option B (bottom of y-axis). Horizontal gray dotted lines represent where subjects were on 266 average 25% more likely to select option A (upper line) or option B (lower line). All time-series traces 267 were smoothed with a 5-trial moving average for visual purposes. The black dots indicate trials where 268 there was a statistically significant difference (p < .05) between the estradiol and placebo group. The 269 number of significant trials was compared to a null distribution (see Methods and materials). B) Cumulative choice difference between the estradiol and placebo group over trials compared to the 270 271 99.9thth percentile null distribution. The thick black line is the difference between the orange and gray 272 lines presented in figure A, and the blue shaded area is the corresponding difference between the 273 standard errors in A. The dark orange area denotes the space in which differences are not significant. 274 Conversely, separation between the lines indicate statistical significance. C) Mean cumulative choice 275 difference between the estradiol and placebo group collapsed across trials. The dashed line represents the mean cumulative choice difference of the 100th percentile of the null distribution. Error bars indicate 276 277 standard error of the mean.

278

279 Estradiol's improvement in accuracy is moderated by DAT1 genotype and 280 reward responsiveness


Following the observed systematic choice difference between both groups, we investigated whether this was reflected in group differences in accuracy. Both groups were equally accurate $(M_{Estradiol} = 57.30 \pm 6.91, M_{Placebo} = 56.80 \pm 7.09, t_{(97.94)} = 0.36, p = .72, Fig. 3A)$, and responded equally fast ($M_{Estradiol} = 0.61 \sec \pm 0.11, M_{Placebo} = 0.62 \sec \pm 0.09, t_{(95.55)} = 0.46, p = .65)$).

However, we predicted that the effect of estradiol on accuracy will be moderated by individual differences in baseline striatal dopamine, as other work has shown interactive effects between task performance and dopamine-related genes ^{18,46}. In our study, we used the DAT1 polymorphism as an index of striatal dopamine with the 9/10 and 10/10 genotypes being associated with high and low striatal dopamine, respectively ⁴⁷.

290 A general linear model revealed an interaction between drug administration and DAT1 genotype on accuracy ($F_{(1, 69)} = 4.10$, p = .047, $\Omega^2 = 0.037$, Fig. 3B) while controlling for 291 292 covariates (see Supplementary Materials). Pairwise comparisons revealed that estradiol administration increased accuracy in subjects with the 9/10 genotype (i.e. high striatal 293 294 dopamine levels; $M = 60.00 \pm 5.36$) compared to those with a 10/10 genotype (i.e. low striatal dopamine levels; 10/10 DAT1, $M = 56.00 \pm 6.51$; $t_{(39.60)} = 2.14$, 95% C/ [0.21, 7.63], p = .04, d 295 = 0.66, BF_{10} = 3.16), while this difference did not exist in the placebo group (9/10 genotype: M 296 297 = 57.21 ±6.60; 10/10 genotype: $M = 56.90 \pm 6.34$; $t_{(30.01)} = 0.15$, p = .88). However, estradiol administration did not improve accuracy in subjects with the 9/10 genotype relative to placebo 298 299 $(9/10: t_{28,48}) = 1.35, p = .19; 10/10: t_{(40,11)} = 1.79, 95\% C/ [-0.41, 6.77], p = .08, d = 0.55, BF_{10}$ 300 = 1.92).

We also predicted that the effect of estradiol would be moderated by subjects' traits related to reward responsiveness such as the one measured by BIS/BAS ^{30,31,33}. Indeed, when we accounted for subjects' reward responsiveness (Fig 3C), we found that those who received estradiol (vs. placebo) were more accurate ($\beta = 24.17 \pm 11.14$, $F_{(1, 85)} = 4.7$, p = 0.03, $\Omega^2 =$

0.008), which was further moderated by reward responsiveness ($F_{(1, 85)} = 4.6$, p = 0.03, $\Omega^2 =$ 305 306 0.036) while controlling for covariates. That is, estradiol enhanced accuracy specifically in subjects who were less reward responsive (r = -0.52, p < .001) with no such correlation in the 307 308 placebo group (r = -0.16, p = 0.27). This result further supports the hypothesis that estradiol 309 administration increased reward sensitivity by enhancing striatal reward prediction errors that increased the saliency of each trial ⁸. In our task, this hypothesis would predict more reward 310 responsive subjects to switch between the choice options more frequently. Indeed, we found 311 312 that within the estradiol group, there was a significant positive correlation between reward 313 responsiveness and switching (r = 0.37, p = 0.009) that was only trending in subjects who received placebo (r = 0.26, p = 0.07). Importantly, the degree of switching negatively predicted 314 subjects' task accuracy ($F_{(1, 98)} = 69.38$, p < .001, $\Omega^2 = 0.41$) across both groups, explaining 315 why more reward responsive subjects who received estradiol were less accurate. 316



317

Fig. 3 A) Mean accuracy split according to drug administration. B) Mean accuracy split according to drug administration and DAT1 polymorphism. C) Accuracy was moderated by reward responsiveness. Green error bars are standard errors of the mean. Dots represent individual subjects. The horizontal dotted line represents grand mean performance collapsed across groups to show the relative change for individual subgroups. * p < .05

323

324 Increased reward sensitivity is observed in increased learning rates

325 Given our observation that estradiol increased reward sensitivity (Fig. 2), the interactive effect

with DAT1 and reward responsiveness (Fig. 3), and our hypothesis that the differences in


327 choice behaviour might occur due to upregulated striatal prediction errors, we predicted that

estradiol would enhance the learning of reward probabilities. In a RL framework this would bereflected in increased learning rates.

To compare learning rates we used the maximum a posteriori estimates of the winning model fitted in a hierarchical Bayesian way ⁴⁸, which included separate learning rates for positive and negative prediction errors, a temperature parameter, and an irreducible noise parameter (see Supplementary Materials for details on model selection and parameter recovery).

This model revealed that estradiol administration increased the learning rates for 335 positive and negative prediction errors compared to placebo (α_{Positive} : $M_{\text{Estradiol}} = 0.47 \pm 0.22$, 336 337 $M_{\text{Placebo}} = 0.37 \pm 0.24, t_{(97.51)} = 2.36, 95\% C/[0.017, 0.19], p = .02, d = 0.47, BF_{10} = 4.77; \alpha_{\text{Negative}}$ $M_{\text{Estradiol}} = 0.45 \pm 0.31, M_{\text{Placebo}} = = 0.27 \pm 0.25, t_{(93.55)} = 3.2, 95\% CI [0.068, 0.29], p = .002, d = 0.002, d =$ 338 0.64, $BF_{10} = 35.03$, Fig. 4A). We also compared both parameters by computing 95% Highest 339 340 Density Interval estimates ⁴⁹ (Fig. 4D) with stronger evidence in favour of the negative learning 341 rate 95% HDI [0.04, 0.39] being higher in subjects who received estradiol compared to the positive learning rate 95% HDI [-0.04, 0.32]. Contrary to our expectations, the observed main 342 effect of estradiol was not moderated by the DAT1 polymorphism in case of either learning 343 rate (α_{Positive} : $F_{(1, 80)} = 0.24$, p = .89, α_{Negative} : $F_{(1, 80)} = 0.12$, p = .73). 344

Finally, to provide construct validation for the obtained parameters, we correlated them with the BIS/BAS Drive subscale measuring motivation for goal-directed behaviour ⁴⁰. We found that both positive and negative learning rates were weakly correlated in subjects who received estradiol ($\alpha_{Positive}$: r = 0.3, p = 0.03, $\alpha_{Negative}$: r = 27, p = 0.06) but not who received placebo ($\alpha_{Positive}$: r = -0.10, p = 0.47, $\alpha_{Negative}$: r = -.09, p = 0.53).



350

Fig. 4 A) Learning rates by drug treatment. Individual dots represent subjects. The red bar represents the median, the box plot represents 75% of data, with the whiskers representing 1.95*IQR. B) 95% highest density interval (HDI) estimates for learning rate differences between both groups. C) Correlation between both learning rates and the drive subscale of BIS/BAS measuring motivation for goal-directed behaviour.

```
356
```

Increased reward sensitivity is driven by differences in stay decisions, choice autocorrelation, and is moderated by the DAT1 genotype

Finally, to more precisely understand the observed difference in choice behaviour between

both groups and DAT1 genotype, we tested whether these differences could be attributed to


361 differences in staying behaviour and choice autocorrelation ^{24,50}.

As would be predicted by increased accuracy in the 9/10 DAT genotype subjects, on 362 363 average these subjects also chose the same option more often after being rewarded for this 364 option before ($M = 1.79 \pm 0.18$; Fig. 5A). This was true when comparing them to subjects with placebo who had the 9/10 genotype ($M = 1.63 \pm 0.22$; $t_{(29.05)} = 2.33$, 95% C/ [0.02, 0.3], p =365 .03, d = 0.80, $BF_{10} = 5.01$), and when comparing them to subjects who had the 10/10 genotype 366 (placebo: $t_{(41,61)} = 2.22, 95\%$ Cl [0.01, 0.27], $p = .03, d = 0.66, BF_{10} = 3.34$; estradiol: ($t_{(38,.86)} =$ 367 2.49, 95% CI [0.03, 0.27], p = .02, d = 0.64, $BF_{10} = 5.95$). In contrast, this difference was not 368 369 observed between both drug groups when not accounting for differences in DAT1 genotype $(t_{(97.94)} = 1.10, p = 0.28)$. In other words, the increase in accuracy by exogenously elevated 370

estradiol in individuals with a 9/10 genotype was reflected in increased decisions to stay withoptions for which they were previously rewarded.

We then extended this metric by examining how subjects' previous choice impacted 373 their current choice. We observed that estradiol administration caused subjects to weigh their 374 375 choice on the previous trial (n - 1) more heavily compared to placebo (Fig. 5B), both when that choice was rewarded ($t_{(97)} = 2.61, 95\%$ Cl [0.073, 0.538], $p = 0.01, d = 0.52, BF_{10} = 8.07$) and 376 irrespective of the outcome $(t_{(97)} = 2.21, 95\% CI [0.034, 0.639], p = .03, d = 0.44, BF_{10} = 3.49).$ 377 378 However, we also observed a decrease in the weight of previous rewarded choices occurring more than one trial ago (n - 4) ($t_{(97)} = 2.59$, 95% C/ [0.064, 0.482], p = 0.01, d = 0.52, $BF_{10} =$ 379 7.93). In other words, while recent rewarded choices carried more weight, choices that were 380 rewarded further in the past carried less weight, which is in line with having higher learning 381 rates compared to the placebo group. 382

When we further split this analysis according to the DAT1 genotype (Fig. 5C), we observed similar results to the ones reported above. Estradiol administration enhanced the weight of the last choice (n – 1) on the current choice in the 9/10 subgroup ($t_{(32)} = 2.12$, 95% *CI* [0.022, 1.027], p = .04, d = 0.73, $BF_{10} = 3.44$) while this was not the case in the 10/10 subgroup ($t_{(48)} = 1.51$, p = .14).



389 Fig. 5 A) Staying behaviour: the average number of trials the same option was selected when that 390 choice was previously rewarded. In both plots, each dot represents a subject, the green error bar 391 represents standard error of the mean. BC) Autocorrelation analysis showing the impact of previous 392 choices from 1 (n-1) to 8 (n-8) trials ago on the current choice. The left panel shows the averaged effect for both options irrespective of whether they were previously rewarded for that choice. The right panel 393 shows the averaged effect for both options when they were previously rewarded for that choice. Both 394 395 line plots are the mean and SEM of z-scored regressor weights. B) shows the split according to estradiol and placebo while C) shows a further split according to the 9/10 and 10/10 DAT1 polymorphism. ** $p < 10^{-10}$ 396 397 .01, * *p* < .05.

398

399 Discussion

We examined the causal role of estradiol in reward processing in men. We show that estradiol affects reward processing and learning in men by increasing reward sensitivity, affecting choice autocorrelation, and increasing explicit awareness of changing reward probabilities. Furthermore, we show that estradiol's effect on accuracy is moderated by subjects' striatal dopaminergic functioning (DAT1 genotype) and reward responsiveness. Finally, we show that from a computational perspective, its effect can be characterised as an increase in learning rates.

407 First, we found that estradiol increased reward sensitivity during reinforcement 408 learning. We observed that both groups systematically choose different options across trials, 409 and on a subset of trials the options each group chose was statistically significantly different. Furthermore, estradiol increased choice autocorrelation for recent choices compared to 410 placebo, while decreasing it for rewarded choice made several trials ago. These findings jointly 411 412 show that by increasing reward sensitivity through upregulated striatal reward prediction errors⁸, estradiol administration caused recent choices and outcomes to be more salient 413 compared to ones occurring further in the past. This interpretation is further supported by the 414 estradiol group having higher learning rates for both positive and negative prediction errors, 415 and subjects explicitly reporting to have observed a higher degree of reward probability 416 changing. Furthermore, it is supported by the effect of estradiol on accuracy being moderated 417 by reward responsiveness. The predicted increase in reward prediction errors caused more 418 419 reward responsive subjects to switch more, in turn reducing their accuracy, while this

relationship did not exist with placebo. The key contribution of the results above is showing,
for the first time, the behavioural and computational effect of estradiol administration on
reinforcement learning in men.

Next, we found that the effect of estradiol on accuracy was moderated by the DAT1 423 genotype, replicating previous correlational studies in women^{6,75}. This result provides 424 evidence for the hypothesis that estradiol may act by amplifying dopamine D1 receptor 425 signalling in humans², as such an effect would also have been predicted by dopamine 426 precursor administration ²⁷ ^{26,36}. To determine the robustness of this effect, we computed 427 428 several behavioural metrics and Bayes factors to show converging evidence for a moderating role of DAT1. We found that estradiol administration significantly increased accuracy in 429 430 subjects with the 9/10 (i.e. high striatal dopamine) compared to ones with the 10/10 genotype 431 (i.e. low striatal dopamine) and that this increase in accuracy was likely driven by increased 432 staying behaviour. That is, subjects with high striatal dopamine chose the same option on 433 more trials, on average, if they were previously rewarded for that choice, compared to the other subgroups. Furthermore, even when they were not rewarded, they showed stronger 434 choice autocorrelation compared to subjects with high striatal dopamine who received a 435 placebo. 436

437 The key contribution of the DAT1-related findings is in reconciling discrepancies of 438 previous correlational work that have been attributed to differences in baseline dopamine levels ^{7,51–53}. That is, we show for the first time that baseline differences in dopamine, indeed, 439 440 play an important role in how estradiol influences reward processing and that these need to be considered in future work aiming at better understanding their relationship. Crucially, the 441 effects we report for accuracy and staying behaviour were not explained by other mechanistic 442 explanations such as those related to androgen receptor functioning, androgen to estrogen 443 conversion, or estrogen receptor functioning (see Supplementary Materials). 444

445 Our results highlight a further feature of how estradiol influences reinforcement 446 learning. We found that estradiol improved accuracy specifically in the high striatal dopamine

447 group which is in contrast to previous research with the dopamine precursor L-dopa where decreased accuracy in such subjects was reported but increased accuracy in subjects with 448 low striatal dopamine was found ²⁶. However, it is known that dopamine precursors impact 449 behaviour in a dose-dependent manner ^{54,55}. This would imply that our estradiol dose acted 450 451 akin to a "low dosage" of a dopamine precursor which is supported by two estradiol administration studies in women. One showing 12 mg of estradiol (i.e. 6 times our dose) 452 decreasing working memory performance³⁴, which was interpreted as an overstimulation of 453 454 dopaminergic transmission. With the other showing a dopamine-like dose-dependent effect of estradiol on hippocampal activity with doses between 2 and 12mg.³⁵. 455

In addition to the effects reported for DAT1, we also provide preliminary evidence that the effect of estradiol is moderated by COMT (see Supplementary Materials). This is in support of the hypothesis that COMT activity is inhibited through estradiol metabolites which in turn increases dopamine availability ^{25 2,56 13,57}.

460 The current study encountered limitations. We recommend future work employing pharmacogenetics to increase their sample size. While our sample size was approximately 461 twice as large compared to most previous work 7,25,34,36,52,53,58,59 and in line with suggestions 462 for the field ², we suspect that an increase in sample size, as in work on other hormones ^{60,61}, 463 464 would have enabled us to make more precise claims at the level of polymorphism subgroup. As no previous estradiol administration study investigated either DAT1 or COMT, we had no 465 basis for the minimal viable sample size, except the general recommendation in ². Our results 466 467 therefore await replication in future administration work.

- 468
- 469
- 470

472 Conclusion

In conclusion, we have shown that estradiol influences choice behaviour by increasing reward sensitivity in healthy young men with distinct behavioural and computational signatures and that these effects are moderated by striatal dopamine-related genes (DAT1) and personality traits related to reward sensitivity. The approach and findings of this study show that understanding the role of estradiol in reward processing has important implications for a better understanding of the biology and neuroscience of human cognition that is moderated by genes in both health and disorder.

480

481 Acknowledgements

The authors would like to thank Christina Faschinger and Isa Krol for their assistance in data collection, Nace Mikus for his help in data collection and analysis suggestions, and Lei Zhang for feedback on the manuscript. The study was supported by the Vienna Science and Technology Fund (WWTF VRG13-007).

486

487 **Conflict of interests**

The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article. RL received travel grants and/or conference speaker honoraria within the last three years from Shire, Heel, Bruker, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of BM Health GmbH since 2019.

492

493

495 **References**

- Schultz, W., Dayan, P. & Montague, P. R. A neural substrate of prediction and reward.
 Science (80-.). 275, 1593–1599 (1997).
- 498 2. Diekhof, E. K. Estradiol and the reward system in humans. *Curr. Opin. Behav. Sci.* 23,
 499 58–64 (2018).
- 3. Saldanha, C. J., Remage-Healey, L. & Schlinger, B. A. Synaptocrine signaling:
- 501 Steroid synthesis and action at the synapse. *Endocr. Rev.* **32**, 532–549 (2011).
- Luine, V. N. Estradiol and cognitive function: Past, present and future. *Horm. Behav.*66, 602–618 (2014).
- 504 5. Thomas, J., Météreau, E., Déchaud, H., Pugeat, M. & Dreher, J. Hormonal treatment 505 increases the response of the reward system at the menopause transition : A

506 counterbalanced randomized placebo-controlled fMRI study.

507 Psychoneuroendocrinology **50**, 167–180 (2014).

- Dreher, J. *et al.* Menstrual cycle phase modulates reward-related neural function in
 women. *PNAS* 104, 2465–2470 (2007).
- 510 7. Diekhof, E. K. & Ratnayake, M. Menstrual cycle phase modulates reward sensitivity

and performance monitoring in young women: Preliminary fMRI evidence.

512 *Neuropsychologia* **84**, 70–80 (2016).

8. Bayer, J., Rusch, T., Zhang, L., Gläscher, J. & Sommer, T. Dose-dependent effects of
estrogen on prediction error related neural activity in the nucleus accumbens of

- healthy young women. *Psychopharmacology (Berl).* (2019) doi:10.1007/s00213-01905409-7.
- 517 9. Lévesque, D. & Di Paolo, T. Rapid conversion of high into low striatal D2-dopamine
 518 receptor agonist binding states after an acute physiological dose of 17β-estradiol.

519 *Neurosci. Lett.* **88**, 113–118 (1988).

- Becker, J. B. Gender Differences in Dopaminergic Function in Striatum and Nucleus
 Accumbens. *Pharmacol. Biochem. Behav.* 64, 803–812 (1999).
- 522 11. Becker, J. B. Direct effect of 17β -estradiol on striatum: Sex differences in dopamine
- 523 release. Synapse **5**, 157–164 (1990).
- Pasqualini, C., Olivier, V., Guibert, B., Frain, O. & Leviel, V. Acute Stimulatory Effect
 of Estradiol on Striatal Dopamine Synthesis. *J. Neurochem.* 65, 1651–1657 (1995).
- 13. Ball, P., Knuppen, R., Haupt, M. & Breuer, H. Interactions Between Estrogens and
- 527 Cateehol Amines III. Studies on the Methylation of Catechol Estrogens, Catechol
- 528 Amines and other Catechols by the Catechol-O-Methyltransferase of Human Liver. *J.*
- 529 Clin. Endocrinol. Metab. **34**, 736–746 (1972).
- 530 14. Yoest, K. E., Quigley, J. A. & Becker, J. B. Rapid effects of ovarian hormones in
 531 dorsal striatum and nucleus accumbens. *Horm. Behav.* **104**, 119–129 (2018).
- 532 15. Schultz, W., Stauffer, R. W. & Lak, A. The phasic dopamine signal maturing: from
 533 reward via behavioural activation to formal economic utility. *Curr. Opin. Neurobiol.* 43,
 534 139–148 (2017).
- 535 16. Glimcher, P. W. Understanding dopamine and reinforcement learning: the dopamine
 536 reward prediction error hypothesis. *PNAS* **108**, 15647–54 (2011).
- 537 17. Frank, M. J., Seeberger, L. C. & O'Reilly, R. C. By carrot or by stick: Cognitive
- reinforcement learning in Parkinsonism. Science (80-.). 306, 1940–1943 (2004).
- 18. Cools, R. *et al.* Striatal Dopamine Predicts Outcome-Specific Reversal Learning and
 Its Sensitivity to Dopaminergic Drug Administration. *J. Neurosci.* 29, 1538–1543
 (2009).
- 19. den Ouden, H. E. M. et al. Dissociable Effects of Dopamine and Serotonin on

543 Reversal Learning. *Neuron* **80**, 1090–1100 (2013).

- 544 20. Jocham, G., Klein, T. A. & Ullsperger, M. Dopamine-Mediated Reinforcement
- 545 Learning Signals in the Striatum and Ventromedial Prefrontal Cortex Underlie Value-
- 546 Based Choices. J. Neurosci. **31**, 1606–1613 (2011).
- 547 21. Jocham, G., Klein, T. a & Ullsperger, M. Differential Modulation of Reinforcement
- 548 Learning by D2 Dopamine and NMDA Glutamate Receptor Antagonism. J. Neurosci.
- 549 **34**, 13151–13162 (2014).
- Eisenegger, C. *et al.* Role of dopamine D2 receptors in human reinforcement learning.
 Neuropsychopharmacology **39**, 2366–2375 (2014).
- 552 23. Swart, J. C. et al. Catecholaminergic challenge uncovers distinct Pavlovian and
- instrumental mechanisms of motivated (in)action. *Elife* **6**, 1–36 (2017).
- Frank, M. J. *et al.* Genetic triple dissociation reveals multiple roles for dopamine in
 reinforcement learning. *PNAS* **104**, 16311–16316 (2007).
- 556 25. Jacobs, E. & D'Esposito, M. Estrogen Shapes Dopamine-Dependent Cognitive
- 557 Processes: Implications for Women's Health. J. Neurosci. **31**, 5286–5293 (2011).
- Eisenegger, C. *et al.* DAT1 Polymorphism Determines L-DOPA Effects on Learning
 about Others ' Prosociality. *PLoS One* 8, e67820 (2013).
- 560 27. Pessiglione, M., Seymour, B., Flandin, G., Dolan, R. J. & Frith, C. D. Dopamine-
- dependent prediction errors underpin reward-seeking behaviour in humans. *Nature*442, 1042–1045 (2006).
- 563 28. Doll, B. B., Bath, K. G., Daw, N. D. & Frank, M. J. Variability in dopamine genes
 564 dissociates model-based and model-free reinforcement learning. *J. Neurosci.* 36,
 565 1211–1222 (2016).
- 566 29. Nemmi, F. et al. Interaction between striatal volume and DAT1 polymorphism predicts

567	working memory development during adolescence. Dev. Cogn. Neurosci. 30, 191-
568	199 (2018).

- 30. Boksem, M. A. S., Tops, M., Kostermans, E. & De Cremer, D. Sensitivity to
- punishment and reward omission: Evidence from error-related ERP components. *Biol. Psychol.* **79**, 185–192 (2008).
- 572 31. Boksem, M. A. S., Tops, M., Wester, A. E., Meijman, T. F. & Lorist, M. M. Error573 related ERP components and individual differences in punishment and reward
 574 sensitivity. *Brain Res.* **1101**, 92–101 (2006).
- Lee, S. H., Ham, B. J., Cho, Y. H., Lee, S. M. & Shim, S. H. Association study of
 dopamine receptor D2Taql A polymorphism and reward-related personality traits in
 healthy Korean young females. *Neuropsychobiology* 56, 146–151 (2008).
- 33. Reuter, M., Schmitz, A., Corr, P. & Hennig, J. Molecular genetics support Gray's
 personality theory: The interaction of COMT and DRD2 polymorphisms predicts the
 behavioural approach system. *Int. J. Neuropsychopharmacol.* 9, 155–166 (2006).
- 34. Sommer, T. *et al.* Effects of the experimental administration of oral estrogen on
 prefrontal functions in healthy young women. *Psychopharmacology (Berl).* 235, 3465–
 3477 (2018).
- 35. Bayer, J., Gläscher, J., Finsterbusch, J., Schulte, L. H. & Sommer, T. Linear and

585 inverted U-shaped dose-response functions describe estrogen effects on

586 hippocampal activity in young women. *Nat. Commun.* **9**, 1–12 (2018).

36. Jakob, K., Ehrentreich, H., Holtfrerich, S. K. C., Reimers, L. & Diekhof, E. K. DAT1-

588 genotype and menstrual cycle, but not hormonal contraception, modulate

reinforcement learning: Preliminary evidence. *Front. Endocrinol. (Lausanne).* 9, 60
(2018).

591 37. Stricker, R. et al. Establishment of detailed reference values for luteinizing hormone,

592	follicle stimulating hormone, estradiol, and progesterone during different phases of
593	the menstrual cycle on the Abbott ARCHITECT analyzer. Clin. Chem. Lab. Med. 44,
594	883–887 (2006).

- 595 38. Eisenegger, C., von Eckardstein, A., Fehr, E. & von Eckardstein, S. Pharmacokinetics
- 596 of testosterone and estradiol gel preparations in healthy young men.
- 597 Psychoneuroendocrinology **38**, 171–178 (2013).
- 598 39. Steyer, R., Schwenkmezger, P., Notz, P. & Eid, M. Testtheoretische Analysen des
- 599 Mehrdimensionalen Befindlichkeitsfragebogen. *Diagnostica* **40**, 320–328 (1994).
- 40. Patton, J. H., Stanford, M. S. & Barratt, E. S. Factor structure of the barratt
 impulsiveness scale. *J. Clin. Psychol.* 51, 768–774 (1995).
- 41. Carver, Charles, S. & White, Teri, L. Behavioral Inhibition, Behavioral Activation, and
 Affective Responses to Impending Reward and Punishment: The BIS/BAS Scales. *J. Pers. Soc. Psychol.* 67, 319–333 (1994).
- Kim, S. H., Yoon, H. S., Kim, H. & Hamann, S. Individual differences in sensitivity to
 reward and punishment and neural activity during reward and avoidance learning. *Soc. Cogn. Affect. Neurosci.* **10**, 1219–1227 (2014).
- 43. Sali, A. W., Anderson, B. A. & Yantis, S. Reinforcement learning modulates the
- stability of cognitive control settings for object selection. *Front. Integr. Neurosci.* 7, 95
 (2013).
- 44. Unger, K., Heintz, S. & Kray, J. Punishment sensitivity modulates the processing of
 negative feedback but not error-induced learning. *Front. Hum. Neurosci.* 6, 186
 (2012).
- Lighthall, N. R., Gorlick, M. A., Schoeke, A., Frank, M. J. & Mather, M. Stress
 Modulates Reinforcement Learning in Younger and Older Adults. *Psychol Aging* 28,
 35–46 (2013).

617	46.	Cools, R. & D'Esposito, M. Inverted-U-shaped dopamine actions on human working
618		memory and cognitive control. Biol. Psychiatry 69, 113–125 (2011).
619	47.	Heinz, A. et al. Genotype influences in vivo dopamine transporter availability in human
620		striatum. Neuropsychopharmacology 22, 133–139 (2000).
621	48.	Ahn, WY., Haines, N. & Zhang, L. Revealing Neurocomputational Mechanisms of
622		Reinforcement Learning and Decision-Making With the hBayesDM Package. Comput.
623		<i>Psychiatry</i> 1 , 24–57 (2017).
624	49.	Ahn, W. et al. Decision-making in stimulant and opiate addicts in protracted
625		abstinence : evidence from computational modeling with pure users. Front. Psychol. 5,
626		1–15 (2014).
627	50.	Daw, N. D., Doherty, J. P. O., Dayan, P., Seymour, B. & Dolan, R. J. Cortical
628		substrates for exploratory decisions in humans. Nature 441, 876-879 (2006).
629	51.	Smith, C. T., Sierra, Y., Oppler, S. H. & Boettiger, C. A. Ovarian Cycle Effects on
630		Immediate Reward Selection Bias in Humans: A Role for Estradiol. J. Neurosci. 34,
631		5468–5476 (2014).
632	52.	Diekhof, E. K. Be quick about it. Endogenous estradiol level, menstrual cycle phase
633		and trait impulsiveness predict impulsive choice in the context of reward acquisition.
634		<i>Horm. Behav.</i> 74 , 186–193 (2015).
635	53.	Reimers, L., Büchel, C. & Diekhof, E. K. How to be patient. The ability to wait for a
636		reward depends on menstrual cycle phase and feedback-related activity. Front.
637		<i>Neurosci.</i> 8 , 401 (2014).
638	54.	Chowdhury, R. et al. Dopamine restores reward prediction errors in old age. Nat.
639		<i>Neurosci.</i> 16 , 648–653 (2013).
640	55.	Chowdhury, R., Guitart-Masip, M., Bunzeck, N., Dolan, R. J. & Düzel, E. Dopamine

641 modulates episodic memory persistence in old age. J. Neurosci. 32, 14193–14204

642 (2012).

643 56. Männistö, P. T. & Kaakkola, S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT 644 inhibitors. Pharmacol. Rev. 51, 593-628 (1999). 645 57. Colzato, L. S. & Hommel, B. Effects of estrogen on higher-order cognitive functions in 646 unstressed human females may depend on individual variation in dopamine baseline 647 levels. Front. Neurosci. 8, 65 (2014). 648 58. Colzato, L. S., Hertsig, G. & Wildenberg, van den Hommel, B. Estrogen modulates 649 inhibitory control in healthy human females: evidence from the stop-signal paradigm. 650 Neuroscience 167, 709-715 (2010). 651 652 59. Colzato, L. S., Pratt, J. & Hommel, B. Estrogen modulates inhibition of return in healthy human females. Neuropsychologia 50, 98-103 (2012). 653 60. Geniole, S. N. et al. Using a Psychopharmacogenetic Approach To Identify the 654 Pathways Through Which—and the People for Whom—Testosterone Promotes 655 Aggression. Psychol. Sci. 30, 481-494 (2019). 656 657 61. Losecaat Vermeer, A. B. et al. Exogenous testosterone increases status-seeking motivation in men with unstable low social status. Psychoneuroendocrinology 113, 658 (2020). 659 62. Sheehan, D. V. et al. The validity of the Mini International Neuropsychiatric Interview 660

661 (MINI) according to the SCID-P and its reliability. *Eur. Psychiatry* **12**, 232–241 (1997).

- 662 63. Fishman, J., Boyar, R. M. & Hellman, L. Influence of body weight on estradiol
 663 metabolism in young women. *J. Clin. Endocrinol. Metab.* 41, 989–991 (1975).
- 664 64. Schneider, J. *et al.* Effects of Obesity on Estradiol Metabolism: Decreased Formation
 665 of Nonuterotropic Metabolites. *J. Clin. Endocrinol. Metab.* 56, 973–978 (1983).

666	65.	Maidenbaum, S., Miller, J., Stein, J. M. & Jacobs, J. Grid-like hexadirectional
667		modulation of human entorhinal theta oscillations. PNAS 115, 10798–10803 (2018).
668	66.	Eisenegger, C., Naef, M., Snozzi, R., Heinrichs, M. & Fehr, E. Prejudice and truth
669		about the effect of testosterone on human bargaining behaviour. Nature 463, 356-359
670		(2010).
671	67.	Aeberli, I., Molinari, L. & Zimmermann, M. B. A composite score combining waist
672		circumference and body mass index more accurately predicts body fat percentage in
673		6- to 13-year-old children. Eur. J. Nutr. 52, 247–253 (2013).
674	68.	Bolker, B. M. et al. Generalized linear mixed models: a practical guide for ecology and
675		evolution. Trends in Ecology and Evolution vol. 24 127–135 (2009).
676	69.	Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects
677		models using lme4. J. Stat. Softw. 67, (2015).
678	70.	Watkins, C. J. C. H. & Dayan, P. Q-learning. Mach. Learn. 8, 279–292 (1992).
679	71.	de Boer, L. et al. Dorsal striatal dopamine D1 receptor availability predicts an
680		instrumental bias in action learning. PNAS 116, 261–270 (2019).
681	72.	Rutledge, R. B. et al. Dopaminergic Drugs Modulate Learning Rates and
682		Perseveration in Parkinson's Patients in a Dynamic Foraging Task. J. Neurosci. 29,
683		15104–15114 (2009).
684	73.	Vehtari, A., Gelman, A. & Gabry, J. Practical Bayesian model evaluation using leave-
685		one-out cross-validation and WAIC. Stat. Comput. 27, 1413–1432 (2017).
686	74.	Rigoux, L., Stephan, K. E., Friston, K. J. & Daunizeau, J. Bayesian model selection for
687		group studies - Revisited. Neuroimage 84, 971–985 (2014).
688	75.	Daunizeau, J., Adam, V. & Rigoux, L. VBA: A Probabilistic Treatment of Nonlinear
689		Models for Neurobiological and Behavioural Data. PLoS Comput. Biol. 10, (2014).

- 690 76. Schaaf, M. E. Van Der, Fallon, S. J., Huurne, N., Buitelaar, J. & Cools, R. Working
- 691 Memory Capacity Predicts Effects of Methylphenidate on Reversal Learning.
- 692 Neuropsychopharmacology **38**, 2011–2018 (2013).
- 693 77. Longcope, C., Kato, T. & Horton, R. Conversion of blood androgens to estrogens in
 694 normal adult men and women. *J. Clin. Invest.* 48, 2191–2201 (1969).
- 695 78. Yaffe, K. et al. Androgen receptor CAG repeat polymorphism is associated with
- cognitive function in older men. *Biol. Psychiatry* **54**, 943–946 (2003).
- 697 79. Beyenburg, S. et al. Androgen receptor mRNA expression in the human
- 698 hippocampus. *Neurosci. Lett.* **294**, 25–28 (2000).
- 89. Kovacs, D. et al. The androgen receptor gene polyglycine repeat polymorphism is
- associated with memory performance in healthy Chinese individuals.
- 701 Psychoneuroendocrinology **34**, 947–952 (2009).
- 702 81. Gillies, G. E. & McArthur, S. Estrogen actions in the brain and the basis for differential
 703 action in men and women: A case for sex-specific medicines. *Pharmacol. Rev.* 62,
 704 155–198 (2010).
- 82. Bayer, J. et al. Estrogen and the male hippocampus: Genetic variation in the
- aromatase gene predicting serum estrogen is associated with hippocampal gray
 matter volume in men. *Hippocampus* 23, 117–121 (2013).
- 708 83. Kravitz, H. M., Meyer, P. M., Seeman, T. E., Greendale, G. A. & Sowers, M. F. R.
- Cognitive Functioning and Sex Steroid Hormone Gene Polymorphisms in Women at
 Midlife. *Am. J. Med.* **119**, 94–102 (2006).
- Almey, A., Milner, T. A. & Brake, W. G. Estrogen receptors in the central nervous
 system and their implication for dopamine-dependent cognition in females. *Horm. Behav.* 74, 125–138 (2015).
- 85. Ma, S. L. et al. Polymorphisms of the estrogen receptor (ESR1) gene and the risk of

715	Alzheimer's disease in a southern Chinese community. Int. Psychogeriatrics 21, 977-
716	986 (2009).
717	
718	
719	
720	
721	
722	
723	
724	
725	
726	
727	
728	
729	
730	
731	
732	
733	
734	
735	

736 Supplementary Materials:

737 A causal role for estradiol in human reinforcement learning

738	Sebastijan Veselic ^{1,2,3*} , Gerhard Jocham ⁴ , Christian Gausterer ⁵ , Bernhard Wagner ⁶ , Miriam
739	Ernhoefer-Reßler ⁶ , Rupert Lanzenberger ⁷ , Clauss Lamm ^{1,8} , Christoph Eisenegger ¹ & Annabel
740	Losecaat Vermeer ^{1*}
741	
742	
743	
744	
745	
746	
747	
748	
749	
750	
751	
752	
753	
754	
755	
756	

757 Methods

758 Subjects

The short version of e-MINI ⁶² was used to screen and exclude those who had a nondiagnosed, disclosed, or a diagnosed psychiatric disorder. Subjects were recruited through social media, web portals, and flyers on university premises. All subjects provided written informed consent and were financially compensated for the completion of the experiment (50€) and received an additional maximum bonus of 40€ (range 7€ – 30€) based on their performance in the all the tasks.

765 Measurement Instruments

766 Experimental Tasks

For each task, we gave subjects paper instructions including control questions to check whether all subjects understood the instructions. All tasks except for the N-BACK task were monetarily incentivised.

770 Reinforcement Learning: In addition to the main 500 trials, subjects were trained on 10 practice trials with two initial options to learn how the task works. The initial two options were 771 then changed (i.e. the sensory cues) before the main trials started. We did this to avoid carry-772 over effects from practice to the main task. As shown in Fig. 1, each trial included three stages: 773 (1) a cue onset stage (5 sec) where subjects had to decide between the two options and press 774 the corresponding key. If they did not respond within that time frame, they would see a warning 775 776 message indicating they should respond and try to be faster next time; (2) a choice feedback stage (1 sec) where subjects received information about both the chosen (thick frame) and 777 unchosen (thin frame) option (yellow - correct, red - wrong); and (3) an inter-trial interval (M =778 779 1.5 sec, jittered between 0.9 to 2.1 sec).

780 **Working memory capacity:** As described in the manuscript, subjects were presented with a 781 sequence of letters one-by-one. For each letter, they had to decide if the current letter was the 782 same as the one presented N trials ago by pressing "R", in case it was not the same they had to press "O". For example, in the 3-back condition, the letter sequence "A B D A A" would require 783 784 subjects to press "R" only to the second occurrence of A. as this was the same letter as the one 785 3 trials ago. The last A in this example sequence is defined as a lure trial, while the other letters 786 were nontarget trials. Lure trials were present only in the 2-BACK and 3-BACK conditions as in ²⁵, and while lure trials were added to keep the task consistent with their implementation. 787 788 we did not further analyse them separately as they were not relevant for our question. In total, 789 there were four blocks per condition. Each block was announced by an instruction lasting for 790 2 sec (Fig. 1A), a fixation cross (1 sec) and a sequence of 20 trials. Each trial was presented for 1 sec with a 1 sec feedback phase and a 1 sec inter-stimulus interval. After every 20 trials, 791 subjects had a 3 sec resting period, before the next block was announced. A lack of response 792 to any cue was considered a miss. 793

794 Procedure

During the first session, we assessed height, weight, abdominal, and visceral fat because these variables could impact estradiol metabolisation ^{63,64}. On the second session subjects applied a topical transparent gel on their chest and shoulders that either contained 2 mg of estradiol (Divigel, Orion Pharma AG, Zug Switzerland) or a placebo. A male experimenter was present to ensure that the subjects applied the gel correctly.

800 Statistical analysis

801 Behavioural analysis

To quantify statistical significance for the cumulative choice difference reported in the manuscript, we employed permutation testing (2000 iterations) by shuffling the responses of each subject and thereby decoupling the label from the responses, thus building a null distribution. The null distribution shows the difference that would be expected from random allocation to the group. To determine significance, we computed z-scores as measures of standardized effect size (e.g. ⁶⁵) by subtracting from the quantity of interest the mean of the 808 null distribution and dividing it by the standard deviation of the null distribution. From this, we
809 were able to use the Fisher-z-transformation to obtain p-values.

810 We used two-sample proportion z-tests to determines the percentage of trials on which 811 the number of subjects who chose option A in one group was statistically significantly different 812 from the other group on a trial-by-trial basis.

For all general linear models reported in the main results, we regressed out several nuisance regressors known to impact estradiol metabolism or affect reinforcement learning behaviour. These included weight, BMI, abdominal and visceral fat ^{63,64}, post-administration cortisol levels ⁴⁵, and beliefs related to having received the drug. This was done because of our previous work showing the impact of beliefs about a hormone on subsequent behaviour, irrespective of whether subjects underwent treatment or received placebo ⁶⁶.

All linear models were compared with BIC and AIC. Unless stated otherwise in the main text, for all reported results the winning model regressed out cortisol levels following administration, beliefs about having received the drug, the certainty of that belief and whether they had observed any changes in themselves, a composite score of weight and BMI that were summed together ⁶⁷ because of their high intrinsic correlation (r = 0.89), visceral, and abdominal fat. For general linear models involving accuracy, we also regressed out reaction times to control for accuracy-speed trade-offs. All nuisance regressors were z-scored.

826 We compared both treatment groups for age and other bodily characteristics (i.e. BMI, 827 height, weight, visceral, and abdominal fat) and potential differences in self-reported mood (MDBF), impulsiveness (BIS-11) and reward responsiveness (BIS/BAS) (see Questionnaires, 828 Table S4 and S5). We used two-tailed independent samples Welch t-tests, or Wilcoxon 829 830 signed-rank test if assumptions of normality were not met, to test whether the groups matched 831 on all variables. To test for mood differences after administration between the treatment groups, we performed an ANCOVA for each of the three subscales of the MDBF questionnaire 832 where we controlled for baseline mood scores. Two-way ANOVAs were further performed on 833

the individual subscales of the BIS-11 questionnaire to investigate whether there was an interaction between the group (estradiol, placebo) and session (pre, post) on impulsiveness.

To compare working memory capacity assessed by the N-BACK task, we analysed target accuracy, reaction times, and d-prime. We analyzed this with an ANOVA containing the between-subject variable group (estradiol, placebo) and within-subject variable for condition together with an interaction term for group and condition.

840 In the supplementary results we used generalized linear mixed effects models using 841 the Ime4 package in R ^{68,69} to investigate whether the interaction between drug, DAT1 or 842 COMT and trial would be predictive of the subjects' chosen option.

843 Computational modelling

To test whether estradiol would increase reward sensitivity and thereby learning, we formalized behaviour within a reinforcement learning framework and fitted several Q-learning models ⁷⁰ with softmax choice rules:

847 Q-learning model (equation 1):

848

$$Q_{t+1}^{A} = Q_{t}^{A} + \alpha (R_{t}^{A} - Q_{t}^{A})$$
(1)

849 Softmax choice rule (equation 2):

850
$$p = \frac{1}{1 + e^{\tau(Q_t^A - Q_t^B)}}$$
(2)

851 Where, t is time, A is option A, Q is subjective value, α is the learning rate, R is the obtained reward, and τ is the temperature parameter. Equations 1 and 2 represent our first model 852 (model 1). In Q-learning, the basic idea is that agents learn subjective values of actions they 853 perform in their environment. Subjective values are learned and updated through a value 854 function (Equation 1) following feedback after each action. A teaching signal known as the 855 learning rate-weighted prediction error dictates how strongly the subjective value will be 856 updated on each action. The prediction error corresponds to the difference between the 857 obtained and expected reward (i.e. the subjective value prior to making the new choice). Within 858

this process, the learning rate dictates how heavily new information will be weighted in proportion to previous information about the option, and therefore how strongly the subjective value will change from its current estimate. The softmax equation then yields the probability of selecting an action given the learning rate and the temperature parameter, which reflects stochasticity of choice behaviour.

By employing computational modelling of this sort, we were able to obtain parameter estimates that quantify the difference in subjects' behaviour, captured by a difference in learning rates. To obtain a more precise account of the effect of estradiol on reward processing, we extended the basic Q-learning model in several ways, as described below.

The first extension (equation 3a and 3b) allowed for separate learning rates for α_{Pos} and α_{Neg} that would differentiate between learning from positive and negative prediction errors.

871
$$Q_{t+1}^{A} = Q_{t}^{A} + \alpha_{Pos}(R_{t}^{A} - Q_{t}^{A})$$
(3a)

872
$$Q_{t+1}^{A} = Q_{t}^{A} + \alpha_{Neg}(R_{t}^{A} - Q_{t}^{A})$$
(3b)

873

The updating with a positive learning rate occurs when the prediction error term $(R_t^A - Q_t^A)$ evaluates to positive while updating with the negative learning rate occurs when the prediction error term evaluates to negative. Furthermore, due to reward stochasticity of our task reward probability distribution (obtained by a Gaussian random walk – Fig. 1B), we added an additional parameter ξ , representing a lapse or irreducible noise parameter ⁷¹ in our choice rule (equation 4):

880
$$p = \frac{1}{1 + e^{\tau(Q_t^A - Q_t^B)}} (1 - \xi) + \frac{\xi}{2}$$
(4)

Finally, we added a perseverance parameter
$$\lambda^{72}$$
 (equation 5):

$$p = \frac{1}{1 + e^{\tau(Q_t^A - Q_t^B + \lambda C)}} (1 - \xi) + \frac{\xi}{2}$$
(5)

884

883

885	Where C = 1, if the same option was chosen on trial n and trial $n+1$, and C = -1 if the opposite
886	was true. In summary, our full model had separate learning rates for positive and negative
887	prediction errors, a choice stochasticity, irreducible noise, and perseverance parameter. All
888	other models were reduced cases of this model and all possible combinations of the described
889	free parameters therefore yielded eight models in total for which we estimated parameters:

890 Table S0. Models and parameters

Model 1	Learning rate, temperature
Model 2	Learning rate, temperature, lapse
Model 3	Learning rate, temperature, perseverence
Model 4	Learning rate, temperature, lapse, perseverence
Model 5	Positive and negative learning rate, temperature
Model 6	Positive and negative learning rate, temperature, lapse
Model 7	Positive and negative learning rate, temperature, perseverence
Model 8	Positive and negative learning rate, temperature, lapse, perseverence

891

892 The model fitting was performed using JAGS and the riags (v 4.9) package in R (v 3.6.0). Each model was run with 5000 samples each with 1000 burn-in samples on three chains. 893 Priors over parameters and hyperparameters were set to default as described in ⁴⁸. We 894 computed the leave one out information criterion using the loo package ⁷³ and used this metric 895 to compare the models. Furthermore, we performed Bayesian model comparison by 896 computing the (protected) exceedance probability ⁷⁴ using the VBA toolbox ⁷⁵ to determine the 897 best model and compare its congruency with the LOOIC measure. Finally, we extracted the 898 posterior predictive density for each subject as a measure of predictive power of the best 899 900 model. This was then compared to the actual behaviour as a measure of static (accuracy 901 collapsed across time) and dynamic (accuracy at each trial across subjects) predictive 902 accuracy. From the obtained maximum a-posteriori estimates we then generated synthetic 903 datasets for each subject and refit the model using synthetic data to assess parameter 904 recovery. We did this by correlating our original and recovered parameters to determine 905 whether the learning rate parameters of the winning model were correlated.

906 Genotyping

907 DNA extraction and quantification

Buccal swabs were collected using sterile cotton swabs (Sarstedt AG, Germany). DNA was
extracted from swabs using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany) and eluted
in a final volume of 50 µL of QIAamp buffer AE (Qiagen). Human nuclear DNA was quantified
using the Applied Biosystems (AB) 7500 real-time PCR instrument (Thermo Fisher Scientific,
Waltham, MA) and the Quantifiler Human Plus quantification Kit (AB) following manufacturer's
recommendations.

914 Typing of repeat length polymorphisms

915 Genomic DNA fragments that contain polymorphic repeat sequences were amplified in two 916 separate reactions: i.e. a multiplex PCR (simultaneously targeting AR(CAG)n, DAT1 VNTR, 917 $\text{Er}\alpha(\text{TA})$ n and $\text{Er}\beta(\text{CA})$ n) and a singleplex PCR (targeting solely AR(GGN)n), respectively.

918 The multiplex PCR was performed using 5 ng template DNA in a reaction mix (total volume of 25 µL) consisting of 1 × GeneAmp PCR buffer (AB), 0.25 mM each dNTP, 2.5 units 919 AmpliTag Gold polymerase (AB) and target specific primers (AR(CAG), DAT1, ERg and Erß: 920 921 including 5'-fluorescent-dye-labeled forward primers; details provided in Table 1). The following protocol was applied using the Veriti 96-well thermal cycler (AB): 35 cycles at 95 °C 922 for 30 seconds, 55 °C for 1 minute, and 72 °C for 1 minute. Before the first cycle, an initial 923 denaturation (95 °C for 5 minutes) was included, and the last cycle was followed by a final 924 925 extension step at 72 °C for 45 minutes.

The singleplex PCR was conducted using 5 ng template DNA in a reaction mix (total volume of 20 μ L) containing target specific primers (AR(GGN)n, details provided in Table S1)), 0.5 μ L Phire Hot Start II DNA polymerase (Thermo Fisher) in 1 × Phire reaction buffer (Thermo Fisher). Amplification was carried out on the Veriti thermal cycler (AB) and included an initial denaturation step at 98 °C for 30 seconds, followed by 33 cycles of 10 seconds at 98 °C, 30 seconds at 60 °C and 30 seconds at 72 °C. The last cycle was followed by a final extension at 72 °C for 10 minutes.

Aliquots of PCR products were diluted with Hi-Di formamide (AB), mixed with internal lane standard LIZ 600 v.2 (AB) and separated on the ABI 3500 Genetic Analyzer applying standard conditions. The number of repeats predicted by the GeneMapper ID-X software (AB) was in full agreement to the actual repeats determined by direct sequencing of PCR products using the BigDye Terminator Sequencing Kit v3.1 (AB) in selected DNA samples.

938Table SI. Panel of loci and primer sets used for the typing of repeat length939polymorphisms

Marker	Location ^b	Primer sequence 5'-3' ^c	Dye	Orientation	Conc. (nM) ^d
AR(GGN)n ^a	chrX:67546447- 67546603(+)	CCTGGCACACTCTCTTCACA	VIC	forward	625
		<u>GTTTCT</u> GGCCGAGTGTAGCCGTAG		reverse	
AR(CAG)n	chrX:67545237- 67545434(+)	CGCGAAGTGATCCAGAACC	6-FAM	forward	200
		<u>GTTTCT</u> AGAACCATCCTCACCCTGCT		reverse	
DAT1 VNTR	chr5:1393559- 1394008(-)	TGTGGTGTAGGGAACGGCCTGAGA	6-FAM	forward	400
		TGTTGGTCTGCAGGCTGCCTGCAT		reverse	
ERα(TA)n	chr6:151806472- 151806594(+)	AACTATCCAAGATTATAGACGCATGA	NED	forward	600
		<u>GTTTCT</u> AACATGCACACGCACATACA		reverse	
Erβ(CA)n	chr14:64253529- 64253650(-)	GTGCTGCGAGCAGAGATA	PET	forward	800
		<u>GTTTCT</u> AATGAGTGGGCCTCCCTTAG		reverse	

941 AR(GGN)n primers only used in singleplex PCR; all other primers combined in a multiplex PCR

942 ^b Chromosome number and genomic location of targeted sequence (orientation provided in brackets) according to

943 UCSC version hg38 (http://genome.ucsc.edu/)

944 ^c The non-specific primer tail is underlined in Italics

945 ^d The final primer concentrations in the reaction mix

946

940

947

949 Typing of the COMT Val158Met polymorphism

950	SNaPshot minisequencing was applied for the typing of Val158Met variants in the COMT
951	gene. Therefore, a 177 bp fragment of genomic DNA harbouring the causative single
952	nucleotide polymorphism (SNP rs4680) in its centre was amplified by PCR. The reaction mix
953	comprised 5 ng template DNA, 1 \times GeneAmp PCR buffer (AB), 0.25 mM each dNTP, 2.5 units
954	AmpliTaq Gold polymerase (AB) and target specific primers (details provided in Table S2) in
955	a total reaction volume of 25 μL . Thermal cycling was performed applying the Veriti cycler (AB)
956	and conditions as follows: 95 °C for 5 min; 35 cycles of 95 °C for 15 seconds, 59 °C for 30
957	seconds and 72 °C for 1 minute; final extension at 72 °C for 5 minutes.

958 Table S2. Primer set used for PCR of the COMT fragment

Marker	Location ^a	Primer sequence 5'-3' ^b	Orientation	Conc. (nM)º
COMT	chr22:19963623- 19963799(+)	GGGCCTACTGTGGCTACTCA	forward	400
		GCCCTTTTTCCAGGTCTGA	reverse	

^a Chromosome number and genomic location of targeted sequence (orientation provided in brackets) according to
 UCSC version hg38 (<u>http://genome.ucsc.edu/</u>).

961

962 PCR products were purified from excess primers and dNTPs by ExoSAP-IT (Thermo Fisher) 963 treatment following manufacturer's recommendations. Minisequencing was conducted on a 964 Veriti thermal cycler (AB) in a total volume of 10 µL containing 3 µL of purified PCR product, 965 5 µL SNaPshot Multiplex Ready Reaction mix (Thermo Fisher) and 2 µL minisequencing 966 primer (2 µM; details see Table 3). The cycling conditions (25 cycles) were as follows: 967 denaturation at 96 °C for 10 seconds, annealing at 50 °C for 5 seconds and extension at 60 968 °C for 30 seconds.

969 Table S3. Minisequencing primer information

SNP sequence variation	Location ^a	Primer sequence 5'-3' ^b	Orientation
G>A	chr22:19963728- 19963747	<u>(GATC)</u> ₄ GGATGGTGGATTTCGCTGGC	forward

970 ^a Chromosome number and genomic location of primer binding site (orientation provided in brackets) according to
 971 UCSC version hg38 (<u>http://genome.ucsc.edu/</u>). The targeted SNP rs4680 is located at position chr22:19963748.

972 ^b The non-specific primer tail is underlined in Italics
 973

ExoSAP-IT treatment was again applied for the clean-up of the minisequencing reaction. 5 µl of purified minisequencing reaction product was then mixed with 9.3 µL Hi-Di formamide (AB) and 0.2 µL of GeneScan-LIZ 120 internal size standard (AB). After a denaturing step for 5 min at 98 °C followed by cooling to 4 °C the fragments were separated on an ABI PRISM 310 Genetic Analyzer (AB) with POP4 polymer and analysed with GeneMapper v3.2 software. Calling of SNP variants based on minisequencing was in full agreement to results from direct sequencing of PCR products in selected DNA samples.

981 Hormone concentrations

982 Quantification of estrone and estradiol in saliva samples was performed with derivatization 983 using pentafluorobenzoyl chloride (PFBCI) and the addition of the isotopically labeled internal 984 standards estrone-d₄ and estradiol-d₅. Organic saliva was reacted with 1.0 mL 1% PFBCI and 985 0.1 mL pyridine at 60°C for 30 min. The derivatization agents were evaporated, the sample 986 was reconstituted with 0.5 mL NaHCO3 and extracted with 1 mL n-hexane. The organic phase was substituted with 0.2 mL dodecane and subjected to optimized GC-MS/MS analysis using 987 988 an Agilent 7890 GC with Agilent DB-17ht 15 m x 0.25 mm x 0.15 µm capillary column connected to an Agilent 7010 tandem mass spectrometer operated in MRM mode using 989 negative chemical ionization at 150°C with methane as a reaction gas (40%, 2 mL/min). 990 Method validation was performed using ion transition m/z 464 -> 400 as a quantifier for estrone 991 992 and m/z 660 -> 596 for estradiol, whereas a LLOQ of 1.92 fg o.c. and 1.94 fg was obtained, 993 respectively.

Quantification of hydrocortisone and testosterone in saliva samples was performed using liquid chromatography tandem mass spectrometry (LCMS/MS), with an Agilent 6460 with electrospray ionization in positive mode coupled to a 1290 UHPLC system. Collision energy was optimized for specific MRM transitions of Hydrocortisone (363.2/121.1 m/z; 363.2/91.1 m/z), Testosterone (289.2/109.1; 289.2/97.1 m/z), 2,3,4-13C3-Hydrocortisone (366.2/124 m/z) and 2,3,4-13C3-Testosterone (292.2/100 m/z). Agilent Poroshell 120 EC-C18 1000 was used for chromatographic separation under reversed phase conditions. The internal 1001 standard preparation and internal standard mixture was prepared containing 2,3,4-13C3-1002 Hydrocortisone; 2,3,4-13C3-Testosterone, 2,4,16,16,17-d5-17b-Estradiol and concentration of 5ng/mL each. Samples were prepared by adding 100 µl internal standards (5 ng/mL) to 1003 1004 500µl plasma or saliva and the steroids were extracted using 4 mL MTBE. After 10 min. overhead shacking, the samples were centrifuged for 5 min, at 3000 rpm and the top MTBE 1005 1006 layer was transferred to a test tube. MTBE was evaporated using a centrivap concentrator at 1007 40°C (Labconco). The residual sample was then re-dissolved in methanol and analyzed by 1008 LC-MS/MS.

1009 **Questionnaires**

1010 **Mood:** To control for a potential confound of mood, tiredness, or alertness from the treatment 1011 affecting subjects' performance ²², we assessed subjects' self-reported mood before and after 1012 administration of the treatment, using the German Multidimensial Mood State Questionnaire 1013 ("Der Mehrdimensionale Befindlichskeitfragebogen - MDBF) ³⁹ Both versions of this 1014 questionnaire (A and B) contain 12 items with a 5-level Likert scale and three subscales that 1015 test for different continuums of mood (Good-Bad [$\alpha_{pre} = .81$, $\alpha_{post} = .77$], Awake-Tired [$\alpha_{pre} =$ 1016 .84, $\alpha_{post} = .87$], Calm-Nervous [$\alpha_{pre} = .73$, $\alpha_{post} = .75$]).

Impulsiveness: We used the Barratt Impulsiveness Scale (BIS-11; ⁴⁰ to measure subjects' 1017 impulsiveness as ⁵² observed that variations in estradiol levels differentially affected women 1018 1019 with low trait as opposed to high trait impulsiveness. BIS-11 is a widely used measure for 1020 impulsiveness with 30 items describing common behaviour and preferences related to (non)impulsiveness which individuals have to rate on a 4-point scale (1 - rarely/never, almost 1021 always/always - 4). The General Impulsiveness ($\alpha_{pre} = .71$, $\alpha_{post} = .75$) factor together with its 1022 three second-order factors (Motor Impulsiveness ($\alpha_{pre} = .47, \alpha_{post} = .54$) Nonplanning 1023 1024 Impulsiveness ($\alpha_{pre} = .6$, $\alpha_{post} = .63$), Attentional Impulsiveness ($\alpha_{pre} = .49$, $\alpha_{post} = .52$) are 1025 reported.

1026 Behavioural inhibition and activation: we measured the trait behavioural activation and 1027 inhibition with the Behavioural inhibiton/Behavioural Activation Scales (BIS/BAS; ⁴¹. The BAS scale is a 24-item questionnaire answered on a four-level scale (1- very true for me. 4 - very 1028 false for me). It is subdivided into Drive (α = .74), Fun Seeking (α = .67), and Reward 1029 1030 Responsiveness (α = .6) while the BIS scale (α = .77) is unidimensional. Drive is thought to measure the persistent pursuit of goals (e.g. "I go out of my way to get the things I want"). Fun 1031 1032 Seeking: the desire for new rewards and willingness to approach events that would be 1033 potentially rewarding (e.g. "I crave excitement and new sensations"), while Reward 1034 Responsiveness focuses on positive responses that would occur if a reward is anticipated 1035 (e.g. "When I am doing well at something I love to keep doing it"). Finally, the BIS scale 1036 measures sensitivity to negative events (e.g. "Criticism or scolding hurts me quite a bit").

1037 Belief probes

In addition, we probed subjects' beliefs and confidence about receiving estradiol (e.g. whether they believed they received estradiol or a placebo, how certain they were of this answer, and whether they noticed any changes). This was done to later regress out the potential contribution of beliefs arising, for example, from subjects researching potential side effects of the hormone prior the experiment. Namely, subjects' beliefs about having received a hormone and beliefs about the effects of a hormone on their performance have previously shown to modulate behaviour independent of whether subjects had actually received it⁶⁶.

- 1045
- 1046
- 1047
- 1048
- 1049
- 1050

1051

1053 **Results**

1054 Matching of both groups

1055 In the first part of the supplementary results, Table S4 and S5 show that our random 1056 assignment was successful as the groups did not differ in any of the measured parameters 1057 before (Table S4) administration and as a function of administration (Table S5). However, we 1058 did observe the expected change in estradiol metabolite concentrations in the estradiol group, 1059 outlined below.

1060

1061 Hormone concentrations

1062 We observed a statistically significant post-administration difference between both groups in log-transformed estradiol concentrations (W = 1545, 95% CI [0.03, 1.87], p < .05) with the 1063 1064 estradiol group having higher estradiol metabolite concentration following administration 1065 (estradiol: $Mdn = 41.77 \pm 531.54$), placebo: $Mdn = 5.55 \pm 230.23$) but not before (estradiol: Mdn= 3.38 ±230.97), placebo: $Mdn = 1.89 \pm 21.92$) compared to the placebo group (W = 1498, 1066 1067 95% CI [-0.05, 1.03], p = .09). We report the median for the values above because even after 1068 log-transforming the metabolite concentrations, they were not distributed normally. Importantly, because we have observed high interindividual variance in estradiol 1069 concentrations prior to administration, we have reason to believe the obtained metabolite 1070 concentrations were contaminated during the handling of the samples following our data 1071 1072 collection. Namely, in previous work such baseline variation was not observed despite an 1073 identical procedure and dosage with the main difference being that serum levels of estradiol were measured there ³⁸. Log-transformed estrone and cortisol concentrations after 1074 1075 administration were also examined showing no differences between both groups. Estrone: (experimental: $Mdn = 8.79 \pm 4226.69$), control: $Mdn = 5.80 \pm 161.99$) (W = 1427, 95% CI [-0.17, 1076 1.05], p = .16), cortisol: (experimental: $Mdn = 0.77 \pm 0.94$), control: $Mdn = 0.73 \pm 1.15$) (W =1077 1078 1207, 95% CI [-0.31, 0.27], *p* = .90).

1080 Bodily measures and behavioural characteristics

As outlined in Table S4, both the estradiol and placebo group were also matched for their weight, height, BMI, visceral, abdominal fat, and individual sub scales of the BIS/BAS questionnaire (Drive, Reward, Fun-Seeking, Behavioural Inhibition). Similarly, separate oneway ANOVAs revealed no interaction for the four subscales of BIS-11 (Table S5) (General: $F_{(1, 195)} = 0.01$, p = 0.91, Attentional: $F_{(1, 195)} = 0.04$, p = .85, Motor: $F_{(1, 195)} = 0.59$, p = .45, nonplanning: $F_{(1, 195)} = 0.08$, p = .78).

1087 Furthermore, we checked whether both the estradiol and placebo group did not differ in pre-existing differences in working memory (Figure S2A, S2B, S2C) in addition to testing 1088 whether administration influenced mood (Figure S2D). By doing so we were able to exclude 1089 1090 differences in working memory and mood leading to the observed results ^{26,76}. Separate 1091 ANCOVAs for the three subscales (Alertness, Mood, Calmness) of the MDBF revealed no 1092 differences in post-administration (Post) scores between the estradiol and placebo group when controlling for baseline scores (Pre) as a covariate (Mood: $F_{(1, 96)} = 0.30$, p = 0.58; 1093 Alertness: $F_{(1, 96)} = 1.35$, p = .25; Calmness: $F_{(1, 96)} = 1.34$, p = .25). Similarly, we observed no 1094 interaction between group membership and post-administration score (Mood: $F_{(1, 96)} = 0.06$, p 1095 1096 = .81; Alertness: $F_{(1, 96)}$ = 1.88, p = .17; Calmness: $F_{(1, 96)}$ = 1.55, p = .22).

1098 Table S4: Descriptive statistics by treatment (Estradiol, Pla	cebo).
--	--------

	Gr	oup			
	Estradiol (n=50)	Placebo (n=50)	n	statistic [95% CI]	p
Age (years)	25.12 (3.63)	24.6 (3.44)	100	1381 [-0.99, 1.49] ¹	0.99
BMI	24.54 (2.65)	24.35 (3.08)	99	1286 [-0.99, 1.99] ¹	0.99
Height (cm)	181.90 (6.88)	180.40 (5.95)	99	1.16 [-1.07, 4.07]	0.94
Weight (kg)	81.09 (9.66)	79.48 (11.44)	99	0.76 [-2.61, 5.83]	0.99
Visc. Fat (%)	6.20 (2.48)	6.06 (2.90)	98	1248 [-0.99, 1.00] ¹	0.99
Abd. Fat (%)	20.66 (5.97)	19.74 (6.32)	98	0.74 [-1.55, 3.38]	0.99

BIS/BAS					
BIS	17.54 (2.80)	18.40 (3.68)	100	-1.32 [-1.86, -0.25]	0.88
Drive	11.72 (1.77)	12.12 (2.32)	100	1074.5	0.91
Reward	11.62 (1.99)	12.46 (2.04)	100	921 ¹	0.18
Fun Seeking	15.88 (2.00)	16.08 (2.17)	100	-0.48 [-1.03, 0.63]	0.99

1099 Note: Values in cells denote M, parentheses denote SD. The superscript 1 denotes the Mann-Whitney-Wilcoxon 1100 1101 W value. For the remaining group comparisons, two-tailed independent samples Welch *t*-tests were employed. In cases where *n* is not equal to N = 100, data was not recorded for that particular variable. p-values are Bonferroni corrected.

1102




Figure S1. A) Accuracy for individual conditions. The red bar represents the median, the box plot represents the most data points, with the whiskers representing 1.95*IQR. Orange depicts the estradiol and gray the placebo group. That is, they represent the division of subjects according to whether they would subsequently be allocated to the estradiol or placebo group. This color convention is used throughout all figures. B) shows density plots for reaction time data for individual conditions. C) shows d' in the most difficult two conditions (2-BACK, 3-BACK) as there were no false alarms in the 0-BACK and 1-BACK, thus accuracy is reduced to d'. D) Average scores prior and post administration for the three subscales of the MDBF.

- 1112
- 1113
- 1114

1115	Furthermore, our working memory (N-BACK) task revealed a comparable picture for accuracy
1116	(Figure S2A), reaction times (Figure S2B), and d-prime (Figure S2C). That is, there was no
1117	statistically significant difference between the estradiol and placebo group in accuracy,
1118	average reaction times, and d-prime. We did observe an expected drop in performance in
1119	terms of decreased accuracy (0-BACK: 92.94 ± 9.34, 1-BACK: 88.06 ± 10.78, 2-BACK: 74.25
1120	\pm 19.38, 3-BACK: 51.56 \pm 17.37), and d-prime (2-BACK: 0.48 \pm 0.14, 3-BACK: 0.32 \pm 0.12),
1121	and increased reaction times (0-BACK: 0.51 \pm 0.05, 1-BACK: 0.56 \pm 0.06, 2-BACK: 0.63 \pm
1122	0.07, 3-BACK: 0.66 \pm 0.07) as the condition became more difficult (i.e. went from 0-BACK to
1123	3-BACK). Separate linear models were used to compute to check for main effects of drug ($F_{(1, 1)}$
1124	$_{196)}$ = 2.01, p = .16) and an interactive effect of drug and condition on d-prime ($F_{(1, 196)}$ = 0.82,
1125	$p = .37$). As mentioned above, we also did this for accuracy (main effect of drug: $F_{(1, 392)} = 1.07$,
1126	$p = .30$; drug*condition interaction: $F_{(3, 392)} = 2.30$, $p = .08$), and reaction times (main effect:
1127	$F_{(1, 347)} = 1.31, p = .25$; drug*condition interaction: $F_{(1, 347)} = 0.99, p = .39$).

1128

		Pre-administr	ation	Post-adm	inistration
	Ν	Estradiol	Placebo	Estradiol	Placebo
MDBF					
Mood	100	17.04 (2.31)	17.36 (2.25)	15.92 (2.41)	16.96 (2.07)
Alertness	100	16.00 (2.77)	16.40 (2.93)	12.94 (3.08)	13.78 (3.30)
Calmness	100	16.48 (2.43)	17.16 (2.38)	16.80 (2.24)	17.36 (2.32)
BIS-11					
General	100	57.86 (7.68)	59.28 (7.45)	59.96 (8.51)	60.46 (7.86)
Motor	100	20.76 (3.00)	21.78 (3.42)	22.02 (3.42)	22.42 (3.65)
Attention	100	14.34 (3.37)	14.14 (2.17)	15.10 (3.30)	14.64 (2.68)
Nonplanning	100	22.76 (3.61)	23.36 (4.29)	22.84 (4.05)	23.40 (4.21)

1130 Note: values in cells denote *M*, values in parentheses denote *SD*.

1131

We observed no correlation between the certainty in the subjects' belief as to whether they had received the drug or placebo (r = 0.02, p = .82), or between the reported observed changes and actually receiving estradiol (r = -0.08, p = .42). This shows that our double-blind procedure was successful, and that our placebo gel preparation was indistinguishable from the actual drug.

1137	Table S6. Frequencies of individual polymorphisms of DAT and COMT genes.
------	--

Polymorphism	Group	Ν	
9/10	Estradiol	18	
9/10	Placebo	16	
10/10	Estradiol	21	
10/10	Placebo	26	
Val/Val	Estradiol	11	
Val/Val	Placebo	9	
Met/Val	Estradiol	23	
Met/Val	Placebo	26	
Met/Met	Estradiol	12	
Met/Met	Placebo	15	

1138 Note: the split according to both COMT and DAT does not sum to 100 because for a few subjects it was not possible 1139 to determine their polymorphism.

- 1140
- 1141

1142 Reinforcement learning task

1143 The role of CYP 19A1, ER α , ER β , CAG, and GGN

Because the results for accuracy, staying, and switching behaviour that we report in the manuscript could also be moderated through other candidate mechanisms, we further analysed these candidate mechanisms together by providing theoretical motivation for the analyses. Here, we first briefly outline their importance and then summarize the observed results.

It is known that androgens are converted to estrogen ⁷⁷. This means that the increase 1149 1150 in estrogen levels arises from this conversion process and the administration more directly. 1151 Furthermore, variation in the length of two functional polymorphisms (CAG – polyglutamine, 1152 and GGN – polyglycine) are known to modulate the functioning of the androgen receptor gene 1153 ⁷⁸. This is important for two reasons. First, our procedure has previously shown to increase 1154 circulating testosterone levels which could have raised estradiol levels whilst being moderated by subjects' androgen receptor characteristics ³⁸. Following from this, previous work has 1155 shown that brain regions important for memory and learning contain androgen receptors ⁷⁹. 1156

1157 Therefore, it could be possible that interindividual differences in both functional polymorphisms 1158 could have moderated our observed results due to interindividual variability. For example, 1159 greater CAG repeat length has previously been associated with lower scores in different cognitive tests in older men ⁷⁸, and GGN repeat length has been associated with immediate 1160 1161 and delayed logical memory recall in women⁸⁰. The described results show a correlation 1162 between individual variability in androgen receptor functioning and cognitive performance. 1163 giving rise to the possibility that CAG and GGN polymorphisms being potential candidate 1164 mechanisms moderating the observed effect of estradiol.

1165 Throughout the conversion process from androgens to estrogens, the CYP19A1 gene encodes instructions for aromatase – the enzyme converting androgens to estrogens ⁸¹. The 1166 single nucleotide polymorphisms (SNPs) associated with the CYP19A1 gene regulate the 1167 1168 metabolism of androgens and mediate brain estrogen activity. Two specific SNPs (rS700518, 1169 rs936306) have been previously shown to have a role in cognitive functioning in humans. For 1170 example, men with the homozygous AA allele have higher estradiol serum levels and greater bilateral posterior hippocampal gray matter volume compared to men with the homozygous 1171 GG allele⁸². While other work has shown a differential impact of homozygous CC alleles 1172 1173 versus homozygous TT alleles on episodic memory recall in women⁸³. Given that our 1174 procedure has previously shown to increase circulating testosterone levels and that polymorphisms of the CYP19A1 gene are known to have a role in cognitive functioning, we 1175 aimed to exclude the possibility that this may have driven our observed effects, and analysed 1176 both single nucleotide polymorphisms of the CYP19A1 gene. 1177

1178 Once androgens are converted to estrogens, estrogen action is mediated through the 1179 estrogen receptors (ER α , ER β). Both receptors are widely distributed throughout the brain, 1180 including regions of importance for cognitive functioning and reward processing ⁸⁴. So far, it 1181 has been shown that ER α is responsible for most of estrogen-related activation. For example, 1182 it has been shown that SNPs of ER α are related to Alzheimer's disease and are associated 1183 with the likelihood of developing cognitive impairment ⁸⁵. We have, therefore, focussed on two 1184 particular SNPs of ER α : rs9340799, rs2234693. In contrast, little is known of a potential impact

of ERβ. As an exploratory measure, we have included repeats of this receptor in our analysisas well.

Of the described candidates (CAG, GGN, CYP 19A1, ERα, ERβ), no test revealed any 1187 1188 effect of interest. There was no interaction between drug group (i.e. estradiol or placebo) and 1189 either the SNPs of ERa: rs9340799 ($F_{(2, 84)} = 0.66$, p = .52), rs2234693 ($F_{(2, 84)} = 0.63$, p = .53) in relation to accuracy. Furthermore, the same was true for the interaction between CAG 1190 repeats and drug group ($F_{(1, 87)} = 0.45$, p = .51), GGN repeats and drug group ($F_{(1, 87)} = 1.31$, p1191 = .26), and SNPs of the CYP19A1 gene and drug group (rs700518 $F_{(2, 84)}$ = 1.84, p = .15, 1192 1193 rs936306 $F_{(2, 84)} = 0.34$, p = .72). In a final examination, we also looked at the repeats of ER β 1194 to determine whether this could have driven any of the observed effects. However, this was 1195 not the case for either recorded variant of ER β (ER β 1: $F_{(1, 87)} = 0.02$, p = .89, ER β 2: $F_{(1, 87)} =$ 1196 0.00, p = .96).

1197 Identical results were obtained for switching behaviour. While we observed a statistically significant interaction between estradiol administration and the COMT 1198 polymorphism (see next section), this was not true for any of the other mechanistic 1199 1200 explanations. That is, no model showed an interaction between drug group and either of the 1201 SNPs of ERa: rs9340799 ($F_{(2, 84)} = 2.90$, p = .06), rs2234693 ($F_{(2, 84)} = 2.88$, p = .06), CAG repeats ($F_{(1, 87)} = 0.10$, p = .76), GGN repeats $F_{(1, 87)} = 1.32$, p = .25), and SNPs of the CYP19A1 1202 1203 gene (rs700518 $F_{(2, 84)} = 1.81$, p = .17, rs936306 $F_{(2, 84)} = 1.08$, p = .35) in relation to switching behaviour. As in the case of accuracy, we also looked at the repeats of ER_β. Again, there was 1204 1205 no statistically significant contribution to switching behaviour from this predictor for either recorded variant of ER β (ER β 1: $F_{(1, 87)}$ = 3.05, p = .08; ER β 2: $F_{(1, 87)}$ = 0.96, p = .33). 1206

We finally repeated the set of analyses for staying behaviour with no effects found of any of these variables: SNPs of ERα: rs9340799 ($F_{(2, 84)} = 1.69, p = .19$), rs2234693 ($F_{(2, 84)} =$ 1.79, p = .17), CAG repeats ($F_{(1, 87)} = 0.38, p = .54$), GGN repeats $F_{(1, 87)} = 0.30, p = .59$), SNPs of the CYP19A1 gene (rs700518 $F_{(2, 84)} = 1.27, p = .29$, rs936306 $F_{(2, 84)} = 0.59, p = .55$), and variant of ERβ (ERβ1: $F_{(1, 87)} = 1.35, p = .25$; ERβ2: $F_{(1, 87)} = 0.86, p = .36$).

In brief, we have shown that the effects related to accuracy, switching, and staying reported in the manuscript did not depend on (1) the overall androgen receptor functioning assessed by CAG and GGN repeat polymorphisms, (2) interindividual variability in the androgen-to-estrogen conversion process via the CYP19A1 gene polymorphism, and (3) estrogen receptor polymorphisms (ER α) or repeats (ER β).


1217

1218 The effect of estradiol administration on choice behaviour is moderated by 1219 polymorphisms of both COMT and DAT1

We directly tested whether the effect of estradiol on choice behaviour is moderated by polymorphisms of dopamine-related genes (e.g. COMT, DAT1) by using generalized linear mixed models. We specifically tested whether the interaction between drug, polymorphism (COMT or DAT1), and trial are a significant predictor of the options they would choose.

Based on the inverted U-shape dopamine hypothesis ⁴⁶, we predicted that estradiol 1224 administration would upregulate reward sensitivity in subjects with low prefrontal dopaminergic 1225 1226 activity (i.e. Val/Val) but would not, or would even impair it, in those with high prefrontal 1227 dopaminergic activity (i.e. Met/Met). The model predictions support this hypothesis as it 1228 predicted that subjects with a Met/Val ($\beta = 0.20 \pm 0.04$, 95% Cl [0.11, 0.28], z = 4.56, p < .001) 1229 and Val/Val genotype ($\beta = 0.37 \pm 0.06$, 95% C/ [0.26, 0.48], z = 6.99, p < .001) were more 1230 likely to select option A as trials progressed when they received estradiol (Fig. S2, S4). Option 1231 A was the more rewarding option throughout the task (percent trials rewarded: M_{optionA} = 53.70%, $M_{\text{optionB}} = 42.91\%$). 1232

Based on the prediction that estradiol indirectly increases striatal dopamine levels, leading to higher reward prediction errors, we expected that subjects with the 9/10 genotype (i.e. high striatal dopamine) would select the higher value option more often, while this would be less often true for subjects with the 10/10 genotype (i.e. low striatal dopamine). This prediction was supported by the model showing that subjects with the 10/10 genotype with placebo (β = -0.12 ± 0.04, *95% Cl* [-0.04, -0.20], *z* = -3.03, *p* < .01) were the most likely to select the lower valued option A throughout task progression, while estradiol administration dampened this slope in subjects with the same 10/10 genotype (Fig. S4). Results from both generalized linear mixed effects models showed that once individual variation was considered, the effect of estradiol administration on choice behaviour across trials was moderated by striatal (DAT1) and prefrontal (COMT) polymorphisms.



1245 Figure S2. Relative choice probability for choosing option A (top of y-axis) vs. choosing stimulus 1 (bottom of y-1246 axis) for the placebo (gray) and estradiol (orange) group split according to both polymorphisms assessed in the 1247 main text: COMT (left panel), DAT (right panel) across trials (1-500). Thick lines represent trial means, shaded 1248 areas denote standard error of the means. The blue line in the background denotes the empirical relative reward 1249 probability which was computed from the probability of stimulus two being rewarding (top of y-axis) - stimulus one 1250 being rewarding (bottom of y-axis). Gray dotted lines represent where subjects were on average 25% more likely 1251 to select option A (upper line) or stimulus 1 (lower line). All time-series traces are smoothed with a 5-trial moving 1252 average for visual purposes. 1253

1244

Figure S2 reveals a differential effect of estradiol administration on choice behaviour that depends on polymorphisms of both COMT and DAT. In the case of the COMT polymorphism this is most clearly visible in the lower left panel. The panel shows that placebo Val/Val subjects exhibited a clear tendency towards option A until trial ~370. After this, they did not reverse back towards choosing it more often despite option A being more rewarding from trial ~420 onwards. This is in contrast with results for subjects with other polymorphisms of COMT and results when subjects were split according to the DAT1 polymorphism. Estradiol Met/Met subjects exhibited choice behaviour more aligned with the reward probability distribution in the beginning at trial ~80 compared to subjects from the placebo group with the same polymorphism. When we then split subjects according DAT1 polymorphism, the estradiol 9/10 subjects can similarly be seen following the reward probability distribution more closely compared to the placebo 9/10.

Because of the results above and because estradiol administration likely results in 1266 increased prefrontal dopamine levels through downregulating COMT enzyme activity ⁵⁶ we 1267 1268 predicted that the interaction between estradiol administration and COMT polymorphism would be predictive of switching behaviour ²⁴. As a measure of switching, we assessed the 1269 1270 number of times the option chosen on trial t was different from the one chosen at trial n + 11271 (i.e. a switch), irrespective of the choice outcome on trial t. Estradiol administration did not 1272 significantly influence switch decisions ($M = 162.12 \pm 56.31$) compared to placebo (M = 168.82) 1273 \pm 68.13). However, we observed a significant interaction of estradiol administration by COMT 1274 genotype ($F_{(2,80)} = 3.22$, p = .05, $\Omega^2 = 0.04$, Fig. S3). The interaction showed that subjects with placebo and a Val/Val genotype (i.e. low prefrontal dopamine availability) switched less often 1275 $(\beta = -84.07 \pm 33.69, p = .02)$ compared to all other groups. As predicted by the inverted U-1276 1277 shaped relationship between prefrontal dopamine levels and behaviour, Val/Val placebo subjects (Val/Val: $M = 132.33 \pm 61.40$) switched less compared to Met/Met placebo subjects 1278 1279 (i.e. associated with high prefrontal dopamine availability; Met/Met: $M = 204.27 \pm 53.52$, $t_{(15.10)}$ = 2.91, 95% C/ [19.25, 124.54], p = .01, d = 1.46). For the estradiol group, this difference was 1280 not present (Val/Val: M = 151.09 ±70.85; Met/Met: M = 178.5 ±55.34; t_(18.96) = 1.03, 95% C/ [-1281 28.28, 83.10], p = .32, d = 0.44). In other words, estradiol administration attenuated naturally 1282 1283 occurring differences in switching behaviour found in subjects with the Met/Met and Val/Val 1284 genotypes that are associated with high and low prefrontal dopamine levels, respectively.





Figure S3. General linear model prediction for switching behaviour (i.e. a change in chosen stimulus on trial t + 1from trial t, independent of choice outcome on trial t). Estradiol administration dampened naturally occurring differences in switching behaviour when subjects were split according to the COMT polymorphism, i.e. whether subjects would switch the stimulus they chose on trial t compared to trial t + 1 irrespective of choice outcome on trial t. Error bars represent SEM.

1291



1300 Formal model comparison

We estimated parameters by fitting several Q-learning models. The best model (model 6, leave one out information criterion (LOOIC) = 58888, Fig. S5A) included separate learning rates for positive and negative prediction errors, a temperature parameter, and an irreducible noise parameter. The model predicted choice behaviour above chance ($t_{(99)} = 13.95, 95\%$ *Cl* [0.64, 0.68], *p* < .001, Fig. S5B) and performed equally well for both groups ($M_{Estradiol} = 66.26$ % ±10.77, $M_{Placebo} = 64.90$ % ±11.85; $t_{(97.115)} = 0.76, 95\%$ *Cl* [-0.03, 0.06], *p* = .45).







Figure S5. A) Leave one out information criterion (LOOIC) value for all employed models. Lower LOOIC indicates better model fit – model two was selected as the best model. B) The overall model accuracy collapsed over time obtained from the posterior predictive density shown for both drug groups separately.

In addition to computing the leave-one-out information criterion to perform model 1313 comparison ⁷³ we similarly computed the exceedance probability of the winning model using 1314 the VBA toolbox ⁷⁵. This value showed a strong preference for the winning model *P*(model 1315 two) = 98%. Furthermore, we computed protected exceedance probability ⁷⁴ as an extension 1316 which, while yielding an expected decrease in the winning model probability, still favoured 1317 1318 model two over other competing models (P(model two) = 12.5%). The likely decrease was due 1319 to the reinforcement learning task not being optimized to detect behavioural differences between the models tested. However, in all reported models, the latent variable of interest, i.e. 1320 1321 the learning rate, remained unaltered. We would therefore expect the increase in learning

rates to be present if we were to select the learning rates from models that best fit individualsubjects.

1324 Validating model

We further tested the model validity and predictions by computing posterior predictive 1325 1326 densities, i.e. what predictions does the model make on a trial-by-trial basis for subjects with 1327 the parameters such as those that were extracted from our subjects. Posterior predictive 1328 densities showed no difference in a fit between both the estradiol and placebo group and 1329 approximated the empirical reward probability distribution (Fig. S6A). To quantify this, we then 1330 compared model predictions from posterior predictive densities with actual subject behaviour 1331 to assess model accuracy collapsed across time (Fig. S6B) showing it performed above 1332 chance and equally well for both groups. We further compared accuracy on each trial across 1333 subjects to ensure that there were no unexpected drops in accuracy. This did not happen as 1334 the model (Fig. S6B) had no discernible drops in performance. We also performed parameter recovery on the winning model where we used the maximum a posteriori estimates reported 1335 in the manuscript, generated data for synthetic subjects, performed parameter estimation on 1336 the synthetic data, and correlated the newly obtained synthetic parameters with original 1337 1338 parameters for each subject. This procedure showed that both original and recovered learning rates correlated with one another (negative: r = 0.33, p < .001, positive: r = -0.34, p < .001). 1339 1340



1343 1344 1345 Figure S6. A) Posterior predictive density computed for both drug groups with overlaid average responses for both drug groups across trials B) Accuracy for both drug groups obtained from the posterior predictive density for both drug groups separately.